drug1_db stringlengths 7 7 | drug2_db stringlengths 7 7 | drug1_id int64 0 1.69k | drug2_id int64 0 1.69k | drug_pair listlengths 2 2 | drug1_name stringlengths 4 85 | drug2_name stringlengths 4 85 | drug1_desc stringlengths 27 1.09k | drug2_desc stringlengths 27 6.14k | label stringclasses 3
values | label_idx int64 0 2 | all_paths listlengths 1 10 | all_paths_str listlengths 1 10 | path_str stringlengths 0 3.57k |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
DB05679 | DB11248 | 1,683 | 1,193 | [
"DDInter1907",
"DDInter1965"
] | Ustekinumab | Zinc gluconate | Ustekinumab is a human immunoglobulin (Ig) G1 kappa monoclonal antibody directed against interleukin(IL)-12 and IL-23, which are cytokines that are involved in immune and inflammatory responses. It was generated via recombinant human IL-12 immunization of human Ig (hu-Ig) transgenic mice. It is a targeted biologic dise... | Zinc gluconate is a zinc salt of gluconic acid comprised of two gluconic acid molecules for each zinc cation (2+). Zinc gluconate is a generally recognized as safe (GRAS) substance by FDA . It is available as a trace mineral supplement and over the counter as a lozenge form for a reduced duration of common colds and wi... | Minor | 0 | [
[
[
1683,
23,
1193
]
],
[
[
1683,
63,
1096
],
[
1096,
23,
1193
]
],
[
[
1683,
25,
725
],
[
725,
62,
1193
]
],
[
[
1683,
24,
1531
],
[
1531... | [
[
[
"Ustekinumab",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Zinc gluconate"
]
],
[
[
"Ustekinumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mycophenolic acid"
... | Ustekinumab may cause a moderate interaction that could exacerbate diseases when taken with Mycophenolic acid and Mycophenolic acid may cause a minor interaction that can limit clinical effects when taken with Zinc gluconate
Ustekinumab may lead to a major life threatening interaction when taken with Satralizumab and S... |
DB01229 | DB01764 | 973 | 805 | [
"DDInter1377",
"DDInter469"
] | Paclitaxel | Dalfopristin | Paclitaxel is a chemotherapeutic agent marketed under the brand name Taxol among others. Used as a treatment for various cancers, paclitaxel is a mitotic inhibitor that was first isolated in 1971 from the bark of the Pacific yew tree which contains endophytic fungi that synthesize paclitaxel. It is available as an intr... | Dalfopristin is a combination of two antibiotics (Dalfopristin and quinupristin) used to treat infections by staphylococci and by vancomycin-resistant Enterococcus faecium. It is not effective against Enterococcus faecalis infections. Dalfopristin inhibits the early phase of protein synthesis in the bacterial ribosome ... | Moderate | 1 | [
[
[
973,
24,
805
]
],
[
[
973,
6,
8374
],
[
8374,
45,
805
]
],
[
[
973,
63,
1101
],
[
1101,
23,
805
]
],
[
[
973,
24,
283
],
[
283,
... | [
[
[
"Paclitaxel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dalfopristin"
]
],
[
[
"Paclitaxel",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)... | Paclitaxel (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Dalfopristin (Compound)
Paclitaxel may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may cause a minor interaction that can limit clinical effects when taken with Dalfopristin
Paclitaxel may c... |
DB00087 | DB11703 | 599 | 405 | [
"DDInter41",
"DDInter9"
] | Alemtuzumab | Acalabrutinib | Alemtuzumab is a humanized monoclonal antibody specific to lymphocyte antigens. It is a recombinant DNA-derived humanized monoclonal antibody (Campath-1H) that is directed against the 21-28 kD cell surface glycoprotein, CD52. The Campath-1H antibody is an IgG1 kappa with the human variable framework and constant region... | To date, acalabrutinib has been used in trials studying the treatment of B-All, myelofibrosis, ovarian cancer, multiple myeloma, and Hodgkin lymphoma, among others. As of October 31, 2017 the FDA approved Astra Zeneca's orally administered Calquence (acalabrutinib, capsules). This Bruton tyrosine kinase (BTK) inhibitor... | Moderate | 1 | [
[
[
599,
24,
405
]
],
[
[
599,
24,
139
],
[
139,
24,
405
]
],
[
[
599,
24,
151
],
[
151,
63,
405
]
],
[
[
599,
63,
1184
],
[
1184,
2... | [
[
[
"Alemtuzumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acalabrutinib"
]
],
[
[
"Alemtuzumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Zidovudine"
],
... | Alemtuzumab may cause a moderate interaction that could exacerbate diseases when taken with Zidovudine and Zidovudine may cause a moderate interaction that could exacerbate diseases when taken with Acalabrutinib
Alemtuzumab may cause a moderate interaction that could exacerbate diseases when taken with Influenza A viru... |
DB00073 | DB08913 | 1,394 | 1,186 | [
"DDInter1608",
"DDInter1561"
] | Rituximab | Radium Ra 223 dichloride | Rituximab is a genetically engineered chimeric murine/human monoclonal antibody directed against the CD20 antigen found on the surface of normal and malignant B lymphocytes. The antibody is an IgG1 kappa immunoglobulin containing murine light and heavy-chain variable region sequences and human constant region sequences... | Radium Ra 223 Dichloride is a radiopharmaceutical containing the radioisotope radium-223 that emits short range but high linear energy alpha particles. As a cation, radium mimics calicum and binds to hydroxyapatite, which is a bone mineral found in areas of high bone turnover as seen in bone metastases. It was first ap... | Moderate | 1 | [
[
[
1394,
24,
1186
]
],
[
[
1394,
25,
1583
],
[
1583,
63,
1186
]
],
[
[
1394,
24,
1362
],
[
1362,
63,
1186
]
],
[
[
1394,
24,
599
],
[
599... | [
[
[
"Rituximab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Radium Ra 223 dichloride"
]
],
[
[
"Rituximab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Sarilumab"
],
[
... | Rituximab may lead to a major life threatening interaction when taken with Sarilumab and Sarilumab may cause a moderate interaction that could exacerbate diseases when taken with Radium Ra 223 dichloride
Rituximab may cause a moderate interaction that could exacerbate diseases when taken with Olaparib and Olaparib may ... |
DB00081 | DB11793 | 273 | 738 | [
"DDInter1838",
"DDInter1297"
] | Tositumomab | Niraparib | Murine IgG2a lambda monoclonal antibody against CD20 antigen (2 heavy chains of 451 residues, 2 lambda chains of 220 residues). It is produced in an antibiotic-free culture of mammalian cells. It can be covalently linked to Iodine 131 (a radioactive isotope of iodine). | Niraparib is an orally active poly (ADP-ribose) polymerase (PARP) inhibitor. By blocking the enzymes responsible for DNA repair, niraparib induces cytotoxicity in cancer cells. Niraparib is selective towards PARP-1 and PARP-2. First approved by the FDA on March 27, 2017, niraparib is used to treat epithelial ovarian, f... | Moderate | 1 | [
[
[
273,
24,
738
]
],
[
[
273,
25,
1213
],
[
1213,
24,
738
]
],
[
[
273,
64,
1578
],
[
1578,
24,
738
]
],
[
[
273,
24,
496
],
[
496,
... | [
[
[
"Tositumomab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Niraparib"
]
],
[
[
"Tositumomab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dasatinib"
],
[
"Dasatinib"... | Tositumomab may lead to a major life threatening interaction when taken with Dasatinib and Dasatinib may cause a moderate interaction that could exacerbate diseases when taken with Niraparib
Tositumomab may lead to a major life threatening interaction when taken with Lepirudin and Lepirudin may cause a moderate interac... |
DB00358 | DB00697 | 1,010 | 876 | [
"DDInter1140",
"DDInter1821"
] | Mefloquine | Tizanidine | Malaria is a protozoan disease that places an enormous burden on human health in endemic areas around the world. The 2020 World Health Organization malaria report indicates a 60% decrease in the global malaria fatality rate between 2000 to 2019. Despite this, malaria remains a significant cause of morbidity and mortali... | Tizanidine is a fast-acting drug used for the management of muscle spasm, which may result from the effects of multiple sclerosis, stroke, an acquired brain injury, or a spinal cord injury . It may also be caused by musculoskeletal injury . Regardless of the cause, muscle spasticity can be an extremely painful and debi... | Moderate | 1 | [
[
[
1010,
24,
876
]
],
[
[
1010,
21,
28882
],
[
28882,
60,
876
]
],
[
[
1010,
23,
112
],
[
112,
62,
876
]
],
[
[
1010,
24,
401
],
[
401,
... | [
[
[
"Mefloquine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tizanidine"
]
],
[
[
"Mefloquine",
"{u} (Compound) causes {v} (Side Effect)",
"Body temperature increased"
],
[
"Body temperature increased"... | Mefloquine (Compound) causes Body temperature increased (Side Effect) and Body temperature increased (Side Effect) is caused by Tizanidine (Compound)
Mefloquine may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clin... |
DB01128 | DB06589 | 918 | 1,250 | [
"DDInter204",
"DDInter1400"
] | Bicalutamide | Pazopanib | Bicalutamide is an oral non-steroidal anti-androgen for prostate cancer. It is comprised of a racemic mixture that is a 50:50 composition of the (R)-bicalutamide and (S)-bicalutamide enantionmers. Bicalutamide binds to the androgen receptor. | Pazopanib is a small molecule inhibitor of multiple protein tyrosine kinases with potential antineoplastic activity. It is developed by GlaxoSmithKline and was FDA approved on October 19, 2009. | Moderate | 1 | [
[
[
918,
24,
1250
]
],
[
[
918,
6,
12523
],
[
12523,
45,
1250
]
],
[
[
918,
21,
29203
],
[
29203,
60,
1250
]
],
[
[
918,
62,
1247
],
[
124... | [
[
[
"Bicalutamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pazopanib"
]
],
[
[
"Bicalutamide",
"{u} (Compound) binds {v} (Gene)",
"CYP2D6"
],
[
"CYP2D6",
"{u} (Gene) is bound by {v} (Compound... | Bicalutamide (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Pazopanib (Compound)
Bicalutamide (Compound) causes Aspartate aminotransferase increased (Side Effect) and Aspartate aminotransferase increased (Side Effect) is caused by Pazopanib (Compound)
Bicalutamide may cause a minor interaction that can li... |
DB00455 | DB04855 | 1,601 | 540 | [
"DDInter1091",
"DDInter602"
] | Loratadine | Dronedarone | Loratadine is a second generation antihistamine used to manage symptoms of allergic rhinitis. A lack of sedative and CNS adverse effects make loratadine, along with other second generation antihistamines, preferable over their 1st generation counterparts in many clinical situations. | Dronedarone is a Class III antiarrhythmic drug that works to restore the normal sinus rhythm in patients with paroxysmal or persistent atrial fibrillation. Atrial fibrillation is a common sustained arrhythmia where the treatment primarily focuses on stroke prevention and symptom management. It is managed by rate contro... | Moderate | 1 | [
[
[
1601,
24,
540
]
],
[
[
1601,
24,
33
],
[
33,
40,
540
]
],
[
[
1601,
6,
8374
],
[
8374,
45,
540
]
],
[
[
1601,
21,
28883
],
[
28883,
... | [
[
[
"Loratadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dronedarone"
]
],
[
[
"Loratadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Amiodarone"
],
[
... | Loratadine may cause a moderate interaction that could exacerbate diseases when taken with Amiodarone and Amiodarone (Compound) resembles Dronedarone (Compound)
Loratadine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Dronedarone (Compound)
Loratadine (Compound) causes Skin disorder (Side Effect) and Ski... |
DB00759 | DB01607 | 1,620 | 1,390 | [
"DDInter1783",
"DDInter1803"
] | Tetracycline | Ticarcillin | Tetracycline is a broad spectrum polyketide antibiotic produced by the Streptomyces genus of Actinobacteria. It exerts a bacteriostatic effect on bacteria by binding reversible to the bacterial 30S ribosomal subunit and blocking incoming aminoacyl tRNA from binding to the ribosome acceptor site. It also binds to some e... | An antibiotic derived from penicillin similar to carbenicillin in action. | Moderate | 1 | [
[
[
1620,
24,
1390
]
],
[
[
1620,
24,
514
],
[
514,
40,
1390
]
],
[
[
1620,
24,
339
],
[
339,
1,
1390
]
],
[
[
1620,
63,
790
],
[
790,
... | [
[
[
"Tetracycline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ticarcillin"
]
],
[
[
"Tetracycline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Benzylpenicillin"
... | Tetracycline may cause a moderate interaction that could exacerbate diseases when taken with Benzylpenicillin and Benzylpenicillin (Compound) resembles Ticarcillin (Compound)
Tetracycline may cause a moderate interaction that could exacerbate diseases when taken with Bacampicillin and Bacampicillin (Compound) resembles... |
DB00191 | DB01067 | 73 | 959 | [
"DDInter1447",
"DDInter826"
] | Phentermine | Glipizide | Phentermine is a sympathomimetic amine anorectic agent and it was introduced in 1959 as part of an anti-obesity combination drug.[A174361, A174364] It is chemically related to amphetamine and it is commonly referred to as an atypical amphetamine. Phentermine has not been reported an addictive potential which allows thi... | Glipizide is an oral hypoglycemic agent in the second-generation sulfonylurea drug class that is used to control blood sugar levels in patients with type 2 diabetes mellitus. It was first introduced in 1984 and is available in various countries including Canada and the U.S. According to the 2018 Clinical Practice Guide... | Moderate | 1 | [
[
[
73,
24,
959
]
],
[
[
73,
24,
245
],
[
245,
40,
959
]
],
[
[
73,
24,
1411
],
[
1411,
1,
959
]
],
[
[
73,
6,
6017
],
[
6017,
45,
... | [
[
[
"Phentermine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glipizide"
]
],
[
[
"Phentermine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glimepiride"
],
[
... | Phentermine may cause a moderate interaction that could exacerbate diseases when taken with Glimepiride and Glimepiride (Compound) resembles Glipizide (Compound)
Phentermine may cause a moderate interaction that could exacerbate diseases when taken with Tolbutamide and Tolbutamide (Compound) resembles Glipizide (Compou... |
DB00440 | DB09418 | 1,548 | 554 | [
"DDInter1874",
"DDInter1501"
] | Trimethoprim | Potassium perchlorate | Trimethoprim is an antifolate antibacterial agent that inhibits bacterial dihydrofolate reductase (DHFR), a critical enzyme that catalyzes the formation of tetrahydrofolic acid (THF) - in doing so, it prevents the synthesis of bacterial DNA and ultimately continued bacterial survival. Trimethoprim is often used in comb... | Potassium perchlorate is an inorganic salt with the chemical formula KClO4. It is a strong oxidizer with the lowest solubility of the alkali metal perchlorates. Potassium is most commonly used in flares and automobile airbags . The use of potassium perchlorate as a component in sealing gaskets for food containers has b... | Major | 2 | [
[
[
1548,
25,
554
]
],
[
[
1548,
25,
948
],
[
948,
62,
176
],
[
176,
23,
554
]
],
[
[
1548,
63,
1645
],
[
1645,
63,
176
],
[
176,
23,
... | [
[
[
"Trimethoprim",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Potassium perchlorate"
]
],
[
[
"Trimethoprim",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Potassium gluconate"
],
[
"P... | Trimethoprim may lead to a major life threatening interaction when taken with Potassium gluconate and Potassium gluconate may cause a minor interaction that can limit clinical effects when taken with Insulin glargine and Insulin glargine may cause a minor interaction that can limit clinical effects when taken with Pota... |
DB00033 | DB06688 | 342 | 1,430 | [
"DDInter949",
"DDInter1677"
] | Interferon gamma-1b | Sipuleucel-T | Human Interferon gamma-1b (140 residues), produced from E. coli. Production of Actimmune is achieved by fermentation of a genetically engineered Escherichia coli bacterium containing the DNA which encodes for the human protein. Purification of the product is achieved by conventional column chromatography. The sequence ... | Sipuleucel-T is a personalized, autologous, cellular immunotherapy. Sipuleucel-T is a therapeutic cancer vaccine for prostate cancer. Sipuleucel-T selectively targets the prostate-specific antigen (PSA) known as prostatic acid phosphatase (PAP) that is expressed in around 95% of prostate cancers. It must be prepared sp... | Moderate | 1 | [
[
[
342,
24,
1430
]
],
[
[
342,
24,
869
],
[
869,
24,
1430
]
],
[
[
342,
25,
676
],
[
676,
63,
1430
]
],
[
[
342,
24,
713
],
[
713,
... | [
[
[
"Interferon gamma-1b",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sipuleucel-T"
]
],
[
[
"Interferon gamma-1b",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Topotec... | Interferon gamma-1b may cause a moderate interaction that could exacerbate diseases when taken with Topotecan and Topotecan may cause a moderate interaction that could exacerbate diseases when taken with Sipuleucel-T
Interferon gamma-1b may lead to a major life threatening interaction when taken with Upadacitinib and U... |
DB00095 | DB10989 | 66 | 496 | [
"DDInter623",
"DDInter858"
] | Efalizumab | Hepatitis A Vaccine | Humanized IgG1 kappa isotype monoclonal antibody that binds to human CD11a. Efalizumab has a molecular weight of approximately 150 kilodaltons and is produced in a Chinese hamster ovary mammalian cell expression system in a nutrient medium containing the antibiotic gentamicin. The FDA approved efalizumab in 2003. It wa... | Hepatitis A viral infection can lead to significant morbidity and mortality, with signs and symptoms that include anorexia, nausea, vomiting, and liver failure. Known by several trade names, such as Havrix and Twinrix, the Hepatitis A vaccine has been formulated for immunization against hepatitis A virus (HAV) infectio... | Moderate | 1 | [
[
[
66,
24,
496
]
],
[
[
66,
24,
1093
],
[
1093,
63,
496
]
],
[
[
66,
24,
4
],
[
4,
24,
496
]
],
[
[
66,
25,
976
],
[
976,
24,
... | [
[
[
"Efalizumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hepatitis A Vaccine"
]
],
[
[
"Efalizumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ixekizumab"
],... | Efalizumab may cause a moderate interaction that could exacerbate diseases when taken with Ixekizumab and Ixekizumab may cause a moderate interaction that could exacerbate diseases when taken with Hepatitis A Vaccine
Efalizumab may cause a moderate interaction that could exacerbate diseases when taken with Omacetaxine ... |
DB00073 | DB08904 | 1,394 | 375 | [
"DDInter1608",
"DDInter342"
] | Rituximab | Certolizumab pegol | Rituximab is a genetically engineered chimeric murine/human monoclonal antibody directed against the CD20 antigen found on the surface of normal and malignant B lymphocytes. The antibody is an IgG1 kappa immunoglobulin containing murine light and heavy-chain variable region sequences and human constant region sequences... | Certolizumab pegol is a pegylated monoclonal antibody against the tumor necrosis factor-alpha (TNF-alpha). It is formed with a humanized Fab fragment of 50 kDa, from an IgG 1 isotype, fused to a 40 kDa polyethylene glycol moiety replacing the Fc antibody region. The absence of the Fc region was ideated to prevent compl... | Major | 2 | [
[
[
1394,
25,
375
]
],
[
[
1394,
23,
1461
],
[
1461,
23,
375
]
],
[
[
1394,
23,
1193
],
[
1193,
62,
375
]
],
[
[
1394,
24,
200
],
[
200,
... | [
[
[
"Rituximab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Certolizumab pegol"
]
],
[
[
"Rituximab",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Vitamin E"
],
[
"Vitamin... | Rituximab may cause a minor interaction that can limit clinical effects when taken with Vitamin E and Vitamin E may cause a minor interaction that can limit clinical effects when taken with Certolizumab pegol
Rituximab may cause a minor interaction that can limit clinical effects when taken with Zinc gluconate and Zinc... |
DB00241 | DB06626 | 288 | 263 | [
"DDInter257",
"DDInter147"
] | Butalbital | Axitinib | Butalbital, or 5-allyl-5-isobutylbarbituric acid, is a derivative of barbituric acid which the hydrogens at position 5 are substituted by an allyl group and an isobutyl group. It is a short-to-intermediate acting member of barbiturates that exhibit muscle-relaxing and anti-anxiety properties that produce central nervou... | Axitinib is a second generation tyrosine kinase inhibitor that works by selectively inhibiting vascular endothelial growth factor receptors (VEGFR-1, VEGFR-2, VEGFR-3). Through this mechanism of action, axitinib blocks angiogenesis, tumour growth and metastases. It is reported to exhibit potency that is 50-450 times hi... | Moderate | 1 | [
[
[
288,
24,
263
]
],
[
[
288,
23,
752
],
[
752,
23,
263
]
],
[
[
288,
24,
392
],
[
392,
24,
263
]
],
[
[
288,
24,
1593
],
[
1593,
6... | [
[
[
"Butalbital",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Axitinib"
]
],
[
[
"Butalbital",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Cimetidine"
],
[
... | Butalbital may cause a minor interaction that can limit clinical effects when taken with Cimetidine and Cimetidine may cause a minor interaction that can limit clinical effects when taken with Axitinib
Butalbital may cause a moderate interaction that could exacerbate diseases when taken with Lapatinib and Lapatinib may... |
DB00572 | DB11130 | 85 | 407 | [
"DDInter136",
"DDInter1344"
] | Atropine | Opium | Atropine is an alkaloid originally synthesized from Atropa belladonna. It is a racemic mixture of d-and l-hyoscyamine, of which only l-hyoscyamine is pharmacologically active.[A251670,L42835] Atropine is generally available as a sulfate salt and can be administered by intravenous, subcutaneous, intramuscular, intraosse... | Opium is the first substance of the diverse group of the opiates. It has been known for a long time, and the first evidence of a poppy culture dates from 5 thousand years by the Sumerians. During the years, opium was used as a sedative and hypnotic, but it was determined to be addictive. Opium is extracted from _Papave... | Moderate | 1 | [
[
[
85,
24,
407
]
],
[
[
85,
24,
662
],
[
662,
24,
407
]
],
[
[
85,
24,
418
],
[
418,
63,
407
]
],
[
[
85,
23,
685
],
[
685,
24,
... | [
[
[
"Atropine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Opium"
]
],
[
[
"Atropine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Carbinoxamine"
],
[
"C... | Atropine may cause a moderate interaction that could exacerbate diseases when taken with Carbinoxamine and Carbinoxamine may cause a moderate interaction that could exacerbate diseases when taken with Opium
Atropine may cause a moderate interaction that could exacerbate diseases when taken with Brexanolone and Brexanol... |
DB00427 | DB00502 | 1,233 | 1,300 | [
"DDInter1879",
"DDInter853"
] | Triprolidine | Haloperidol | First generation histamine H1 antagonist used in allergic rhinitis; asthma; and urticaria. It is a component of cough and cold medicines. It may cause drowsiness. | Haloperidol is a high potency first-generation (typical) antipsychotic and one of the most frequently used antipsychotic medications used worldwide. While haloperidol has demonstrated pharmacologic activity at a number of receptors in the brain, it exerts its antipsychotic effect through its strong antagonism of the do... | Moderate | 1 | [
[
[
1233,
24,
1300
]
],
[
[
1233,
24,
78
],
[
78,
1,
1300
]
],
[
[
1233,
24,
543
],
[
543,
63,
1300
]
],
[
[
1233,
63,
1242
],
[
1242,
... | [
[
[
"Triprolidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Haloperidol"
]
],
[
[
"Triprolidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Droperidol"
],
... | Triprolidine may cause a moderate interaction that could exacerbate diseases when taken with Droperidol and Droperidol (Compound) resembles Haloperidol (Compound)
Triprolidine may cause a moderate interaction that could exacerbate diseases when taken with Loperamide and Loperamide may cause a moderate interaction that ... |
DB00377 | DB00420 | 1,494 | 508 | [
"DDInter1382",
"DDInter1532"
] | Palonosetron | Promazine | Palonosetron (INN, trade name Aloxi) is an antagonist of 5-HT3 receptors that is indicated for the prevention and treatment of chemotherapy-induced nausea and vomiting (CINV). It is the most effective of the 5-HT3 antagonists in controlling delayed CINV nausea and vomiting that appear more than 24 hours after the first... | A phenothiazine with actions similar to chlorpromazine but with less antipsychotic activity. It is primarily used in short-term treatment of disturbed behavior and as an antiemetic. It is currently not approved for use in the United States. | Moderate | 1 | [
[
[
1494,
24,
508
]
],
[
[
1494,
25,
1264
],
[
1264,
63,
508
]
],
[
[
1494,
24,
1630
],
[
1630,
1,
508
]
],
[
[
1494,
25,
1164
],
[
1164,
... | [
[
[
"Palonosetron",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promazine"
]
],
[
[
"Palonosetron",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Doxepin"
],
[
"Doxepin",
... | Palonosetron may lead to a major life threatening interaction when taken with Doxepin and Doxepin may cause a moderate interaction that could exacerbate diseases when taken with Promazine
Palonosetron may cause a moderate interaction that could exacerbate diseases when taken with Perphenazine and Perphenazine (Compound... |
DB00431 | DB01069 | 1,503 | 401 | [
"DDInter1072",
"DDInter1533"
] | Lindane | Promethazine | An organochlorine insecticide that has been used as a pediculicide and a scabicide. Lindane has been banned in California, United Kingdom, Australia, and many western countries due to concerns about neurotoxicity and adverse effects on the environment. In Canada, Lindane is not recommmended as a first-line therapy due ... | Promethazine, originally known as 3,277 R.P., is an N-dimethylaminopropyl derivative of [phenothiazine] that was developed in France in 1946. Promethazine antagonizes a variety of receptors, allowing it to be used for a number of indications including allergic reactions, pain, sedation, nausea, and vomiting.[A189907,A1... | Moderate | 1 | [
[
[
1503,
24,
401
]
],
[
[
1503,
24,
146
],
[
146,
24,
401
]
],
[
[
1503,
24,
1264
],
[
1264,
63,
401
]
],
[
[
1503,
21,
28787
],
[
28787,... | [
[
[
"Lindane",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promethazine"
]
],
[
[
"Lindane",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Propiomazine"
],
[
... | Lindane may cause a moderate interaction that could exacerbate diseases when taken with Propiomazine and Propiomazine may cause a moderate interaction that could exacerbate diseases when taken with Promethazine
Lindane may cause a moderate interaction that could exacerbate diseases when taken with Doxepin and Doxepin m... |
DB00736 | DB11963 | 660 | 1,045 | [
"DDInter676",
"DDInter465"
] | Esomeprazole | Dacomitinib | Esomeprazole, sold under the brand name Nexium, is a proton pump inhibitor (PPI) medication used for the management of gastroesophageal reflux disease (GERD), for gastric protection to prevent recurrence of stomach ulcers or gastric damage from chronic use of NSAIDs, and for the treatment of pathological hypersecretory... | Dacomitinib, designed as (2E)-N-16-4-(piperidin-1-yl) but-2-enamide, is an oral highly selective quinazalone part of the second-generation tyrosine kinase inhibitors which are characterized by the irreversible binding at the ATP domain of the epidermal growth factor receptor family kinase domains. Dacomitinib was devel... | Major | 2 | [
[
[
660,
25,
1045
]
],
[
[
660,
63,
80
],
[
80,
24,
1045
]
],
[
[
660,
24,
187
],
[
187,
24,
1045
]
],
[
[
660,
62,
109
],
[
109,
24... | [
[
[
"Esomeprazole",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dacomitinib"
]
],
[
[
"Esomeprazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Amphetamine"
],
[
"Amph... | Esomeprazole may cause a moderate interaction that could exacerbate diseases when taken with Amphetamine and Amphetamine may cause a moderate interaction that could exacerbate diseases when taken with Dacomitinib
Esomeprazole may cause a moderate interaction that could exacerbate diseases when taken with Pirfenidone an... |
DB00570 | DB09054 | 147 | 384 | [
"DDInter1936",
"DDInter905"
] | Vinblastine | Idelalisib | Antitumor alkaloid isolated from Vinca rosea. (Merck, 11th ed.) | Idelalisib is a phosphoinositide 3-kinase inhibitor indicated in the treatment of chronic lymphocytic leukemia (CLL), relapsed follicular B-cell non-Hodgkin lymphoma (FL), and relapsed small lymphocytic lymphoma (SLL). For the treatment of relapsed CLL, it is currently indicated as a second-line agent in combination wi... | Major | 2 | [
[
[
147,
25,
384
]
],
[
[
147,
24,
555
],
[
555,
23,
384
]
],
[
[
147,
23,
307
],
[
307,
23,
384
]
],
[
[
147,
24,
1618
],
[
1618,
2... | [
[
[
"Vinblastine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Idelalisib"
]
],
[
[
"Vinblastine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Netupitant"
],
[
"Netupita... | Vinblastine may cause a moderate interaction that could exacerbate diseases when taken with Netupitant and Netupitant may cause a minor interaction that can limit clinical effects when taken with Idelalisib
Vinblastine may cause a minor interaction that can limit clinical effects when taken with Modafinil and Modafinil... |
DB00816 | DB01410 | 1,674 | 423 | [
"DDInter1346",
"DDInter375"
] | Orciprenaline | Ciclesonide | A beta-adrenergic agonist used in the treatment of asthma and bronchospasms. [PubChem] | Ciclesonide is a glucocorticoid used to treat obstructive airway diseases. It is marketed under the brand name Alvesco. | Minor | 0 | [
[
[
1674,
23,
423
]
],
[
[
1674,
62,
1573
],
[
1573,
1,
423
]
],
[
[
1674,
62,
1351
],
[
1351,
40,
423
]
],
[
[
1674,
23,
1486
],
[
1486,
... | [
[
[
"Orciprenaline",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Ciclesonide"
]
],
[
[
"Orciprenaline",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Prednisone"
],
[... | Orciprenaline may cause a minor interaction that can limit clinical effects when taken with Prednisone and Prednisone (Compound) resembles Ciclesonide (Compound)
Orciprenaline may cause a minor interaction that can limit clinical effects when taken with Flunisolide and Flunisolide (Compound) resembles Ciclesonide (Comp... |
DB04908 | DB09046 | 1,671 | 1,094 | [
"DDInter741",
"DDInter1201"
] | Flibanserin | Metreleptin | Flibanserin is the first drug to be approved for hypoactive sexual desire disorder (HSDD) in premenopausal women by the FDA in August 2015. It was originally developed as an antidepressant medication by Boehringer Ingelheim, but showed lack of efficacy in trials and was further developed as a hypoactive sexual disorder... | Metreleptin, a recombinant analog of the human hormone leptin, is an orphan drug used to treat complications of leptin deficiency in people with lipodystrophy. Lipodystrophies include a range of disorders characterized by the reduction, absence, or altered distribution of adipose tissue. Complications of lipodystrophy ... | Moderate | 1 | [
[
[
1671,
24,
1094
]
],
[
[
1671,
62,
168
],
[
168,
23,
1094
]
],
[
[
1671,
23,
1135
],
[
1135,
63,
1094
]
],
[
[
1671,
24,
866
],
[
866,
... | [
[
[
"Flibanserin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metreleptin"
]
],
[
[
"Flibanserin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Bortezomib"
],
[
... | Flibanserin may cause a minor interaction that can limit clinical effects when taken with Bortezomib and Bortezomib may cause a minor interaction that can limit clinical effects when taken with Metreleptin
Flibanserin may cause a minor interaction that can limit clinical effects when taken with Naloxegol and Naloxegol ... |
DB00405 | DB04946 | 128 | 924 | [
"DDInter517",
"DDInter907"
] | Dexbrompheniramine | Iloperidone | Dexbrompheniramine maleate is an antihistamine agent that is used for the treatment of allergic conditions, such as hay fever or urticaria. | Iloperidone is an atypical antipsychotic for the treatment of schizophrenia symptoms. Hoechst Marion Roussel Inc. researched the drug until May 1996. In June 1997 they gave the research rights to Titan Pharmaceuticals, who gave the worldwide development, manufacturing, and marketing rights to Novartis in August 1998. O... | Moderate | 1 | [
[
[
128,
24,
924
]
],
[
[
128,
24,
1664
],
[
1664,
1,
924
]
],
[
[
128,
24,
519
],
[
519,
40,
924
]
],
[
[
128,
6,
10104
],
[
10104,
... | [
[
[
"Dexbrompheniramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iloperidone"
]
],
[
[
"Dexbrompheniramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Risperidon... | Dexbrompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Risperidone and Risperidone (Compound) resembles Iloperidone (Compound)
Dexbrompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Paliperidone and Paliperidone (Compound) resembles... |
DB00333 | DB06273 | 576 | 980 | [
"DDInter1166",
"DDInter1824"
] | Methadone | Tocilizumab | Methadone is a potent synthetic analgesic that works as a full µ-opioid receptor (MOR) agonist and N-methyl-d-aspartate (NMDA) receptor antagonist. As a full MOR agonist, methadone mimics the natural effects of the body's opioids, endorphins, and enkephalins through the release of neurotransmitters involved in pain tra... | Tocilizumab is a recombinant humanized monoclonal antibody IL-6 receptor inhibitor used to treat inflammatory and autoimmune conditions. It was first described in the literature in 2003 when Chugai, a subsidiary of Roche began developing IL-6 inhibiting monoclonal antibodies. Tocilizumab was granted FDA approval on 8 J... | Moderate | 1 | [
[
[
576,
24,
980
]
],
[
[
576,
1,
494
],
[
494,
24,
980
]
],
[
[
576,
24,
597
],
[
597,
24,
980
]
],
[
[
576,
25,
1487
],
[
1487,
24... | [
[
[
"Methadone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tocilizumab"
]
],
[
[
"Methadone",
"{u} (Compound) resembles {v} (Compound)",
"Disopyramide"
],
[
"Disopyramide",
"{u} may cause a mode... | Methadone (Compound) resembles Disopyramide (Compound) and Disopyramide may cause a moderate interaction that could exacerbate diseases when taken with Tocilizumab
Methadone may cause a moderate interaction that could exacerbate diseases when taken with Chloramphenicol and Chloramphenicol may cause a moderate interacti... |
DB00987 | DB01044 | 1,224 | 246 | [
"DDInter460",
"DDInter809"
] | Cytarabine | Gatifloxacin | A pyrimidine nucleoside analog that is used mainly in the treatment of leukemia, especially acute non-lymphoblastic leukemia. Cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA. Its actions are specific for the S phase of the cell cycle. It also has antiviral and immunosuppressant p... | Gatifloxacin is an antibiotic agent and a member of the fourth-generation fluoroquinolone family. It works by inhibiting the bacterial enzymes DNA gyrase and topoisomerase IV. It was first introduced by Bristol-Myers Squibb in 1999 under the brand name Tequin® for the treatment of respiratory tract infections. Gatiflox... | Minor | 0 | [
[
[
1224,
23,
246
]
],
[
[
1224,
62,
739
],
[
739,
1,
246
]
],
[
[
1224,
23,
945
],
[
945,
40,
246
]
],
[
[
1224,
62,
1467
],
[
1467,
... | [
[
[
"Cytarabine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Gatifloxacin"
]
],
[
[
"Cytarabine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Lomefloxacin"
],
[
... | Cytarabine may cause a minor interaction that can limit clinical effects when taken with Lomefloxacin and Lomefloxacin (Compound) resembles Gatifloxacin (Compound)
Cytarabine may cause a minor interaction that can limit clinical effects when taken with Sparfloxacin and Sparfloxacin (Compound) resembles Gatifloxacin (Co... |
DB00041 | DB00446 | 1,648 | 597 | [
"DDInter38",
"DDInter351"
] | Aldesleukin | Chloramphenicol | Aldesleukin, a lymphokine, is produced by recombinant DNA technology using a genetically engineered E. coli strain containing an analog of the human interleukin-2 gene. Genetic engineering techniques were used to modify the human IL-2 gene, and the resulting expression clone encodes a modified human interleukin-2. This... | An antibiotic first isolated from cultures of _Streptomyces venezuelae_ in 1947 but now produced synthetically. It has a relatively simple structure and was the first broad-spectrum antibiotic to be discovered. It acts by interfering with bacterial protein synthesis and is mainly bacteriostatic. (From Martindale, The E... | Moderate | 1 | [
[
[
1648,
24,
597
]
],
[
[
1648,
24,
1230
],
[
1230,
23,
597
]
],
[
[
1648,
24,
318
],
[
318,
62,
597
]
],
[
[
1648,
24,
599
],
[
599,
... | [
[
[
"Aldesleukin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chloramphenicol"
]
],
[
[
"Aldesleukin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Citalopram"
],
... | Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Citalopram and Citalopram may cause a minor interaction that can limit clinical effects when taken with Chloramphenicol
Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Escitalopram and... |
DB01227 | DB11057 | 1,301 | 720 | [
"DDInter1043",
"DDInter1223"
] | Levacetylmethadol | Mineral oil | Levacetylmethadol is a narcotic analgesic with a long onset and duration of action. It is used mainly in the treatment of narcotic dependence. Levacetylmethadol was withdrawn from use in the European Union due to its high risk of QT interval prolongation. The production of levacetylmethadol in the US has ceased as well... | Mineral oil, or paraffin oil, is a mixture of higher alkanes from a mineral source, such as petroleum. Petroleum mineral oil is manufactured from crude oils by vacuum distillation to produce several distillates and a residual oil that are then further refined. During the modern refining process, aromatics are reduced b... | Moderate | 1 | [
[
[
1301,
24,
720
]
],
[
[
1301,
25,
927
],
[
927,
63,
720
]
],
[
[
1301,
25,
1151
],
[
1151,
24,
720
]
],
[
[
1301,
40,
675
],
[
675,
... | [
[
[
"Levacetylmethadol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mineral oil"
]
],
[
[
"Levacetylmethadol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Encorafenib"
],
[
... | Levacetylmethadol may lead to a major life threatening interaction when taken with Encorafenib and Encorafenib may cause a moderate interaction that could exacerbate diseases when taken with Mineral oil
Levacetylmethadol may lead to a major life threatening interaction when taken with Sunitinib and Sunitinib may cause ... |
DB00656 | DB00983 | 827 | 480 | [
"DDInter1851",
"DDInter776"
] | Trazodone | Formoterol | Trazodone is triazolopyridine derivative from the serotonin receptor antagonists and reuptake inhibitors (SARIs) class of antidepressants. It is used in adults and has been shown to be comparable in efficacy to other drugs such as tricyclic antidepressants (TCAs), selective serotonin reuptake inhibitors (SSRIs), and se... | Formoterol is an inhaled beta<sub>2</sub>-agonist used in the management of COPD and asthma that was first approved for use in the United States in 2001. It acts on bronchial smooth muscle to dilate and relax airways, and is administered as a racemic mixture of its active (R;R)- and inactive (S;S)-enantiomers. A major ... | Moderate | 1 | [
[
[
827,
24,
480
]
],
[
[
827,
24,
1148
],
[
1148,
63,
480
]
],
[
[
827,
6,
12523
],
[
12523,
45,
480
]
],
[
[
827,
21,
28963
],
[
28963,
... | [
[
[
"Trazodone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Formoterol"
]
],
[
[
"Trazodone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Isoprenaline"
],
[
... | Trazodone may cause a moderate interaction that could exacerbate diseases when taken with Isoprenaline and Isoprenaline may cause a moderate interaction that could exacerbate diseases when taken with Formoterol
Trazodone (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Formoterol (Compound)
Trazodone (Compo... |
DB06616 | DB14783 | 594 | 287 | [
"DDInter224",
"DDInter574"
] | Bosutinib | Diroximel fumarate | Bosutinib is a 7-alkoxy-3-quinolinecarbonitrile that functions as a potent, dual SRC and ABL tyrosine kinase inhibitor indicated for chronic myelogenous leukemia (CML), specifically Philadelphia chromosome-positive (Ph+) CML. Philadelphia chromosome is a hallmark of CML due to the reciprocal translocation t(9;22)(q34;q... | Multiple Sclerosis (MS) is a chronic, debilitating neurological disease that can lead to profound cognitive and physical symptoms, severely affecting quality of life. It is the main cause of neurological disability not caused by trauma in the young adult population of both North America and Europe. Relapsing-remitting ... | Moderate | 1 | [
[
[
594,
24,
287
]
],
[
[
594,
63,
1101
],
[
1101,
24,
287
]
],
[
[
594,
25,
384
],
[
384,
24,
287
]
],
[
[
594,
64,
1220
],
[
1220,
... | [
[
[
"Bosutinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diroximel fumarate"
]
],
[
[
"Bosutinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bexarotene"
],
... | Bosutinib may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may cause a moderate interaction that could exacerbate diseases when taken with Diroximel fumarate
Bosutinib may lead to a major life threatening interaction when taken with Idelalisib and Idelalisib may ... |
DB00197 | DB06343 | 1,324 | 1,379 | [
"DDInter1881",
"DDInter1766"
] | Troglitazone | Teprotumumab | Troglitazone was withdrawn in 2000 due to risk of hepatotoxicity. It was superseded by [pioglitazone] and [rosiglitazone]. | Teprotumumab is a fully human IgG1 monoclonal antibody directed against the human insulin-like growth factor-1 receptor. Following a clinical trial in which its efficacy in the treatment of thyroid eye disease (TED) was assessed, it received "breakthrough therapy" designation from the FDA in 2016 and was approved by th... | Moderate | 1 | [
[
[
1324,
24,
1379
]
],
[
[
1324,
24,
1296
],
[
1296,
63,
1379
]
],
[
[
1324,
24,
1254
],
[
1254,
24,
1379
]
],
[
[
1324,
63,
1179
],
[
11... | [
[
[
"Troglitazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Teprotumumab"
]
],
[
[
"Troglitazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin degludec"
... | Troglitazone may cause a moderate interaction that could exacerbate diseases when taken with Insulin degludec and Insulin degludec may cause a moderate interaction that could exacerbate diseases when taken with Teprotumumab
Troglitazone may cause a moderate interaction that could exacerbate diseases when taken with Ins... |
DB00341 | DB00477 | 1,242 | 216 | [
"DDInter343",
"DDInter363"
] | Cetirizine | Chlorpromazine | Cetirizine, also commonly known as _Zyrtec_, is an orally active second-generation histamine H1 antagonist proven effective in the treatment of various allergic symptoms, such as sneezing, coughing, nasal congestion, hives, and other symptoms,. One of the most common uses for this drug is for a condition called _allerg... | The prototypical phenothiazine antipsychotic drug. Like the other drugs in this class, chlorpromazine's antipsychotic actions are thought to be due to long-term adaptation by the brain to blocking dopamine receptors. Chlorpromazine has several other actions and therapeutic uses, including as an antiemetic and in the tr... | Moderate | 1 | [
[
[
1242,
24,
216
]
],
[
[
1242,
1,
1321
],
[
1321,
40,
216
]
],
[
[
1242,
24,
1178
],
[
1178,
1,
216
]
],
[
[
1242,
24,
902
],
[
902,
... | [
[
[
"Cetirizine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chlorpromazine"
]
],
[
[
"Cetirizine",
"{u} (Compound) resembles {v} (Compound)",
"Prochlorperazine"
],
[
"Prochlorperazine",
"{u} (Co... | Cetirizine (Compound) resembles Prochlorperazine (Compound) and Prochlorperazine (Compound) resembles Chlorpromazine (Compound)
Cetirizine may cause a moderate interaction that could exacerbate diseases when taken with Trifluoperazine and Trifluoperazine (Compound) resembles Chlorpromazine (Compound)
Cetirizine may cau... |
DB08873 | DB12001 | 74 | 564 | [
"DDInter221",
"DDInter7"
] | Boceprevir | Abemaciclib | Boceprevir is a direct acting antiviral medication used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV). HCV is a single-stranded RNA virus that is categorized into nine distinct genotypes, with genotype 1 being the most common in... | Abemaciclib is an antitumor agent and dual inhibitor of cyclin-dependent kinases 4 (CDK4) and 6 (CDK6) that are involved in the cell cycle and promotion of cancer cell growth in case of unregulated activity. On September 28, 2017, FDA granted approval of abemaciclib treatment under the market name Verzenio for the trea... | Major | 2 | [
[
[
74,
25,
564
]
],
[
[
74,
24,
868
],
[
868,
24,
564
]
],
[
[
74,
64,
392
],
[
392,
24,
564
]
],
[
[
74,
25,
982
],
[
982,
63,
... | [
[
[
"Boceprevir",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Abemaciclib"
]
],
[
[
"Boceprevir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vemurafenib"
],
[
"Vemurafe... | Boceprevir may cause a moderate interaction that could exacerbate diseases when taken with Vemurafenib and Vemurafenib may cause a moderate interaction that could exacerbate diseases when taken with Abemaciclib
Boceprevir may lead to a major life threatening interaction when taken with Lapatinib and Lapatinib may cause... |
DB06616 | DB12010 | 594 | 214 | [
"DDInter224",
"DDInter785"
] | Bosutinib | Fostamatinib | Bosutinib is a 7-alkoxy-3-quinolinecarbonitrile that functions as a potent, dual SRC and ABL tyrosine kinase inhibitor indicated for chronic myelogenous leukemia (CML), specifically Philadelphia chromosome-positive (Ph+) CML. Philadelphia chromosome is a hallmark of CML due to the reciprocal translocation t(9;22)(q34;q... | Fostamatinib has been investigated for the treatment and basic science of Rheumatoid Arthritis and Immune Thrombocytopenic Purpura (ITP). It was approved on April 17, 2018, under the trade name Tavalisse for use in ITP [L2644, FDA Label]. Fostamatinib has also been granted orphan drug status by the FDA . Recently, fost... | Moderate | 1 | [
[
[
594,
24,
214
]
],
[
[
594,
25,
976
],
[
976,
24,
214
]
],
[
[
594,
64,
723
],
[
723,
24,
214
]
],
[
[
594,
63,
1005
],
[
1005,
2... | [
[
[
"Bosutinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fostamatinib"
]
],
[
[
"Bosutinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tofacitinib"
],
[
"Tofacitin... | Bosutinib may lead to a major life threatening interaction when taken with Tofacitinib and Tofacitinib may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib
Bosutinib may lead to a major life threatening interaction when taken with Aprepitant and Aprepitant may cause a moderate in... |
DB00953 | DB01191 | 742 | 1,039 | [
"DDInter1611",
"DDInter518"
] | Rizatriptan | Dexfenfluramine | Rizatriptan is a second-generation triptan and a selective 5-HT<sub>1B and 5-HT1D</sub> receptor agonist. Used in the treatment of migraines, rizatriptan was first approved in the US in 1998. Rizatriptan is available in oral tablets, orally disintegrating tablets (wafers), and oral film formulations. | Dexfenfluramine, also marketed under the name Redux, is a serotoninergic anorectic drug. For a fairly limited time during the middle of the nineties, the US FDA had approved it for use in managing weight loss. However, following multiple concerns about the cardiovascular side-effects of the drug, such approval was with... | Major | 2 | [
[
[
742,
25,
1039
]
],
[
[
742,
6,
7950
],
[
7950,
45,
1039
]
],
[
[
742,
63,
475
],
[
475,
24,
1039
]
],
[
[
742,
25,
222
],
[
222,
... | [
[
[
"Rizatriptan",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dexfenfluramine"
]
],
[
[
"Rizatriptan",
"{u} (Compound) binds {v} (Gene)",
"CYP1A2"
],
[
"CYP1A2",
"{u} (Gene) is bound by {v} (Compound)",
"... | Rizatriptan (Compound) binds CYP1A2 (Gene) and CYP1A2 (Gene) is bound by Dexfenfluramine (Compound)
Rizatriptan may cause a moderate interaction that could exacerbate diseases when taken with Morphine and Morphine may cause a moderate interaction that could exacerbate diseases when taken with Dexfenfluramine
Rizatripta... |
DB09312 | DB11627 | 967 | 1,367 | [
"DDInter106",
"DDInter860"
] | Antithymocyte immunoglobulin (rabbit) | Hepatitis B Vaccine (Recombinant) | Rabbit anti-thymocyte globulin. Thymoglobulin is a polyclonal antibody that suppresses certain types of immune cells responsible for acute organ rejection in transplant patients. Thymoglobulin is a mixture of antibodies intended to bind to various cell surface antigens. The most common mode of action of Thymoglobulin i... | Hepatitis B Vaccine is an ingredient in the EMA-withdrawn product Quintanrix. It is marketed in Canada as Engerix B. It is also a part of Twinrix (Hep A/Hep B vaccine) available also in Canada. The hepatitis B virus induces a severe form of viral hepatitis. Other causative agents are hepatitis A virus, and the non-A, n... | Moderate | 1 | [
[
[
967,
24,
1367
]
],
[
[
967,
64,
1064
],
[
1064,
24,
1367
]
],
[
[
967,
63,
259
],
[
259,
24,
1367
]
],
[
[
967,
25,
375
],
[
375,
... | [
[
[
"Antilymphocyte immunoglobulin (horse)",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hepatitis B Vaccine (Recombinant)"
]
],
[
[
"Antilymphocyte immunoglobulin (horse)",
"{u} may lead to a major life threatening intera... | Antilymphocyte immunoglobulin (horse) may cause a moderate interaction that could exacerbate diseases when taken with Hepatitis B Vaccine (Recombinant)
Antilymphocyte immunoglobulin (horse) may lead to a major life threatening interaction when taken with Cladribine and Cladribine may cause a moderate interaction that c... |
DB00500 | DB08870 | 24 | 850 | [
"DDInter1831",
"DDInter228"
] | Tolmetin | Brentuximab vedotin | A non-steroidal anti-inflammatory agent (anti-inflammatory agents, NON-steroidal) similar in mode of action to indomethacin. | Brentuximab vedotin, also known as Adcetris®, is an antibody-drug conjugate that combines an anti-CD30 antibody with the drug monomethyl auristatin E (MMAE). It is an anti-neoplastic agent used in the treatment of Hodgkin's lymphoma and systemic anaplastic large-cell lymphoma. Brentuximab vedotin was initially approved... | Moderate | 1 | [
[
[
24,
24,
850
]
],
[
[
24,
24,
267
],
[
267,
24,
850
]
],
[
[
24,
1,
1062
],
[
1062,
24,
850
]
],
[
[
24,
40,
886
],
[
886,
24,
... | [
[
[
"Tolmetin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brentuximab vedotin"
]
],
[
[
"Tolmetin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Naltrexone"
],
... | Tolmetin may cause a moderate interaction that could exacerbate diseases when taken with Naltrexone and Naltrexone may cause a moderate interaction that could exacerbate diseases when taken with Brentuximab vedotin
Tolmetin (Compound) resembles Tolcapone (Compound) and Tolcapone may cause a moderate interaction that co... |
DB00512 | DB01024 | 91 | 1,096 | [
"DDInter1916",
"DDInter1252"
] | Vancomycin | Mycophenolic acid | Antibacterial obtained from Streptomyces orientalis. It is a glycopeptide related to ristocetin that inhibits bacterial cell wall assembly and is toxic to kidneys and the inner ear. As of January 29 2018, CutisPharma's Firvanq is the only FDA approved vancomycin oral liquid treatment option available for the the treatm... | Mycophenolic acid is a potent immunosuppressant agent that inhibits _de novo_ purine biosynthesis. It was derived from _Penicillium stoloniferum_, and has also shown antibacterial, antifungal and antiviral properties.. Mycophenolic acid is used in immunosuppressive regimens as part of a triple therapy that includes a c... | Moderate | 1 | [
[
[
91,
24,
1096
]
],
[
[
91,
24,
955
],
[
955,
1,
1096
]
],
[
[
91,
21,
28666
],
[
28666,
60,
1096
]
],
[
[
91,
25,
629
],
[
629,
2... | [
[
[
"Vancomycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mycophenolic acid"
]
],
[
[
"Vancomycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mycophenolate mofeti... | Vancomycin may cause a moderate interaction that could exacerbate diseases when taken with Mycophenolate mofetil and Mycophenolate mofetil (Compound) resembles Mycophenolic acid (Compound)
Vancomycin (Compound) causes Nervous system disorder (Side Effect) and Nervous system disorder (Side Effect) is caused by Mycopheno... |
DB00358 | DB00934 | 1,010 | 413 | [
"DDInter1140",
"DDInter1124"
] | Mefloquine | Maprotiline | Malaria is a protozoan disease that places an enormous burden on human health in endemic areas around the world. The 2020 World Health Organization malaria report indicates a 60% decrease in the global malaria fatality rate between 2000 to 2019. Despite this, malaria remains a significant cause of morbidity and mortali... | Maprotiline is a tetracyclic antidepressant with similar pharmacological properties to tricyclic antidepressants (TCAs). Similar to TCAs, maprotiline inhibits neuronal norepinephrine reuptake, possesses some anticholinergic activity, and does not affect monoamine oxidase activity. It differs from TCAs in that it does n... | Moderate | 1 | [
[
[
1010,
24,
413
]
],
[
[
1010,
63,
1302
],
[
1302,
40,
413
]
],
[
[
1010,
63,
847
],
[
847,
1,
413
]
],
[
[
1010,
6,
4973
],
[
4973,
... | [
[
[
"Mefloquine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Maprotiline"
]
],
[
[
"Mefloquine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Protriptyline"
],
... | Mefloquine may cause a moderate interaction that could exacerbate diseases when taken with Protriptyline and Protriptyline (Compound) resembles Maprotiline (Compound)
Mefloquine may cause a moderate interaction that could exacerbate diseases when taken with Atomoxetine and Atomoxetine (Compound) resembles Maprotiline (... |
DB05294 | DB11110 | 1,069 | 603 | [
"DDInter1917",
"DDInter1115"
] | Vandetanib | Magnesium citrate | Vandetanib is an oral once-daily kinase inhibitor of tumour angiogenesis and tumour cell proliferation with the potential for use in a broad range of tumour types. On April 6 2011, vandetanib was approved by the FDA to treat nonresectable, locally advanced, or metastatic medullary thyroid cancer in adult patients. | Magnesium citrate is a low volume and osmotic cathartic agent. The cathartic action works primarily through the high osmolarity of the solution which draws large amounts of fluid into space where is used. Magnesium citrate is considered by the FDA as an approved inactive ingredient for approved drug products under the ... | Moderate | 1 | [
[
[
1069,
24,
603
]
],
[
[
1069,
64,
57
],
[
57,
24,
603
]
],
[
[
1069,
25,
1616
],
[
1616,
24,
603
]
],
[
[
1069,
25,
484
],
[
484,
... | [
[
[
"Vandetanib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium citrate"
]
],
[
[
"Vandetanib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Arsenic trioxide"
],
[
... | Vandetanib may lead to a major life threatening interaction when taken with Arsenic trioxide and Arsenic trioxide may cause a moderate interaction that could exacerbate diseases when taken with Magnesium citrate
Vandetanib may lead to a major life threatening interaction when taken with Histrelin and Histrelin may caus... |
DB00912 | DB01045 | 473 | 463 | [
"DDInter1581",
"DDInter1590"
] | Repaglinide | Rifampicin | Repaglinide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It belongs to the meglitinide class of short-acting insulin secretagogues, which act by binding to β cells of the pancreas to stimulate insulin release. Repaglinide induces an early insulin response... | A semisynthetic antibiotic produced from Streptomyces mediterranei. It has a broad antibacterial spectrum, including activity against several forms of Mycobacterium. In susceptible organisms it inhibits DNA-dependent RNA polymerase activity by forming a stable complex with the enzyme. It thus suppresses the initiation ... | Moderate | 1 | [
[
[
473,
24,
463
]
],
[
[
473,
63,
690
],
[
690,
40,
463
]
],
[
[
473,
6,
15333
],
[
15333,
45,
463
]
],
[
[
473,
63,
1101
],
[
1101,
... | [
[
[
"Repaglinide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rifampicin"
]
],
[
[
"Repaglinide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rifabutin"
],
[
... | Repaglinide may cause a moderate interaction that could exacerbate diseases when taken with Rifabutin and Rifabutin (Compound) resembles Rifampicin (Compound)
Repaglinide (Compound) binds SLCO1B1 (Gene) and SLCO1B1 (Gene) is bound by Rifampicin (Compound)
Repaglinide may cause a moderate interaction that could exacerba... |
DB00731 | DB01136 | 1,144 | 772 | [
"DDInter1269",
"DDInter305"
] | Nateglinide | Carvedilol | Nateglinide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It belongs to the meglitinide class of short-acting insulin secretagogues, which act by binding to β cells of the pancreas to stimulate insulin release. Nateglinide is an amino acid derivative that ... | Carvedilol is a racemic mixture where the S(-) enantiomer is both a beta and alpha-1 adrenoceptor blocker, and the R(+) enantiomer is an alpha-1 adrenoceptor blocker.[L7889,L7892] It is currently used to treat heart failure, left ventricular dysfunction, and hypertension.[L7889,L7892] The dual action of carvedilol is a... | Moderate | 1 | [
[
[
1144,
24,
772
]
],
[
[
1144,
6,
12523
],
[
12523,
45,
772
]
],
[
[
1144,
21,
28734
],
[
28734,
60,
772
]
],
[
[
1144,
63,
542
],
[
542... | [
[
[
"Nateglinide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Carvedilol"
]
],
[
[
"Nateglinide",
"{u} (Compound) binds {v} (Gene)",
"CYP2D6"
],
[
"CYP2D6",
"{u} (Gene) is bound by {v} (Compound)... | Nateglinide (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Carvedilol (Compound)
Nateglinide (Compound) causes Immune system disorder (Side Effect) and Immune system disorder (Side Effect) is caused by Carvedilol (Compound)
Nateglinide may cause a moderate interaction that could exacerbate diseases when t... |
DB01233 | DB12161 | 1,311 | 730 | [
"DDInter1197",
"DDInter512"
] | Metoclopramide | Deutetrabenazine | Diabetic gastroparesis is a condition that causes frequent nausea and vomiting, which has a negative impact on quality of life and poses a significant burden on the healthcare system. Metoclopramide is a dopamine antagonist used to treat nausea and vomiting that may be associated with diabetic gastroparesis in addition... | Deutetrabenazine is a novel, highly selective vesicular monoamine transporter 2 (VMAT2) inhibitor indicated for the management of chorea associated with Huntington’s disease. It is a hexahydro-dimethoxybenzoquinolizine derivative and a deuterated . The presence of deuterium in deutetrabenazine increases the half-lives ... | Major | 2 | [
[
[
1311,
25,
730
]
],
[
[
1311,
63,
100
],
[
100,
24,
730
]
],
[
[
1311,
24,
1374
],
[
1374,
24,
730
]
],
[
[
1311,
62,
1010
],
[
1010,
... | [
[
[
"Metoclopramide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Deutetrabenazine"
]
],
[
[
"Metoclopramide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brompheniramine"
],
... | Metoclopramide may cause a moderate interaction that could exacerbate diseases when taken with Brompheniramine and Brompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Deutetrabenazine
Metoclopramide may cause a moderate interaction that could exacerbate diseases when taken wi... |
DB00307 | DB00367 | 1,101 | 566 | [
"DDInter202",
"DDInter1061"
] | Bexarotene | Levonorgestrel | Bexarotene (Targretin) is an antineoplastic agent indicated by the FDA for Cutaneous T cell lymphoma. It has been used off-label for lung cancer, breast cancer, and Kaposi's sarcoma. | Levonorgestrel (LNG) is a synthetic progestogen similar to [Progesterone] used in contraception and hormone therapy.[A181988,T659] Also known as Plan B, it is used as a single agent in emergency contraception, and as a hormonal contraceptive released from an intrauterine device, commonly referred to as an IUD. Some of ... | Major | 2 | [
[
[
1101,
25,
566
]
],
[
[
1101,
64,
1336
],
[
1336,
40,
566
]
],
[
[
1101,
25,
873
],
[
873,
40,
566
]
],
[
[
1101,
24,
35
],
[
35,
... | [
[
[
"Bexarotene",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Levonorgestrel"
]
],
[
[
"Bexarotene",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Etonogestrel"
],
[
"Etonogestrel",
... | Bexarotene may lead to a major life threatening interaction when taken with Etonogestrel and Etonogestrel (Compound) resembles Levonorgestrel (Compound)
Bexarotene may lead to a major life threatening interaction when taken with Norgestimate and Norgestimate (Compound) resembles Levonorgestrel (Compound)
Bexarotene may... |
DB01211 | DB08907 | 609 | 1,344 | [
"DDInter393",
"DDInter280"
] | Clarithromycin | Canagliflozin | Clarithromycin, a semisynthetic macrolide antibiotic derived from erythromycin, inhibits bacterial protein synthesis by binding to the bacterial 50S ribosomal subunit. Binding inhibits peptidyl transferase activity and interferes with amino acid translocation during the translation and protein assembly process. Clarith... | Canagliflozin, also known as _Invokana_, is a sodium-glucose cotransporter 2 (SGLT2) inhibitor used in the management of type 2 diabetes mellitus along with lifestyle changes including diet and exercise [FDA label]. It was initially approved by the FDA in 2013 for the management of diabetes and later approved in 2018 f... | Moderate | 1 | [
[
[
609,
24,
1344
]
],
[
[
609,
24,
549
],
[
549,
1,
1344
]
],
[
[
609,
6,
4973
],
[
4973,
45,
1344
]
],
[
[
609,
21,
28873
],
[
28873,
... | [
[
[
"Clarithromycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Canagliflozin"
]
],
[
[
"Clarithromycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dapagliflozin"
... | Clarithromycin may cause a moderate interaction that could exacerbate diseases when taken with Dapagliflozin and Dapagliflozin (Compound) resembles Canagliflozin (Compound)
Clarithromycin (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Canagliflozin (Compound)
Clarithromycin (Compound) causes Pancreatitis (S... |
DB11793 | DB12498 | 738 | 76 | [
"DDInter1297",
"DDInter1238"
] | Niraparib | Mogamulizumab | Niraparib is an orally active poly (ADP-ribose) polymerase (PARP) inhibitor. By blocking the enzymes responsible for DNA repair, niraparib induces cytotoxicity in cancer cells. Niraparib is selective towards PARP-1 and PARP-2. First approved by the FDA on March 27, 2017, niraparib is used to treat epithelial ovarian, f... | Mogamulizumab is a humanized monoclonal antibody (mAb) directed against CC chemokine receptor 4 (CCR4) for the treatment of Mycosis Fungoides (MF) and Sézary Syndrome (SS), the most common subtypes of cutaneous T-cell lymphoma. Cutaneous T-cell lymphomas occur when certain white blood cells, called T cells, become canc... | Moderate | 1 | [
[
[
738,
24,
76
]
],
[
[
738,
63,
1531
],
[
1531,
24,
76
]
],
[
[
738,
24,
987
],
[
987,
63,
76
]
],
[
[
738,
24,
270
],
[
270,
24,
... | [
[
[
"Niraparib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mogamulizumab"
]
],
[
[
"Niraparib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Canakinumab"
],
[
... | Niraparib may cause a moderate interaction that could exacerbate diseases when taken with Canakinumab and Canakinumab may cause a moderate interaction that could exacerbate diseases when taken with Mogamulizumab
Niraparib may cause a moderate interaction that could exacerbate diseases when taken with Vibrio cholerae CV... |
DB01041 | DB06414 | 770 | 655 | [
"DDInter1789",
"DDInter703"
] | Thalidomide | Etravirine | A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, thalidomide was withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of inflammatory disorders and cancers. Thalidomide displays immunosuppressive and anti-angiogenic activity through modulating ... | Etravirine is an antiretroviral agent more specifically classified as a Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI). Etraverine is used clinically for the treatment of human immunodeficiency virus type 1 (HIV-1) infection. On January 18, 2007, the FDA granted accelerated approved for the use of etravirine 10... | Moderate | 1 | [
[
[
770,
24,
655
]
],
[
[
770,
24,
786
],
[
786,
40,
655
]
],
[
[
770,
6,
6017
],
[
6017,
45,
655
]
],
[
[
770,
21,
28723
],
[
28723,
... | [
[
[
"Thalidomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Etravirine"
]
],
[
[
"Thalidomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rilpivirine"
],
[... | Thalidomide may cause a moderate interaction that could exacerbate diseases when taken with Rilpivirine and Rilpivirine (Compound) resembles Etravirine (Compound)
Thalidomide (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Etravirine (Compound)
Thalidomide (Compound) causes Malnutrition (Side Effect) and M... |
DB00023 | DB06372 | 305 | 259 | [
"DDInter127",
"DDInter1594"
] | Asparaginase Escherichia coli | Rilonacept | Asparaginase derived from _Escherichia coli_ (L-asparagine amidohydrolase, EC 3.5.1.1) is an enzyme responsible for the metabolism of L-asparagine, by catalyzing L-asparagine into L-aspartic acid and ammonia. It also facilitates the production of oxaloacetate which is needed for general cellular metabolism. Asparaginas... | Rilonacept is a dimeric fusion protein consisting of portions of IL-1R and the IL-1R accessory protein linked to the Fc portion of immunoglobulin G1. Rilonacept functions as an interleukin 1 inhibitor and is used in the treatment of CAPS, also known as cryopyrin-associated periodic syndromes, including familial cold au... | Moderate | 1 | [
[
[
305,
24,
259
]
],
[
[
305,
24,
1197
],
[
1197,
24,
259
]
],
[
[
305,
24,
1367
],
[
1367,
63,
259
]
],
[
[
305,
25,
770
],
[
770,
... | [
[
[
"Asparaginase Escherichia coli",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rilonacept"
]
],
[
[
"Asparaginase Escherichia coli",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v... | Asparaginase Escherichia coli may cause a moderate interaction that could exacerbate diseases when taken with Norethisterone and Norethisterone may cause a moderate interaction that could exacerbate diseases when taken with Rilonacept
Asparaginase Escherichia coli may cause a moderate interaction that could exacerbate ... |
DB00069 | DB00277 | 367 | 1,031 | [
"DDInter946",
"DDInter1791"
] | Interferon alfacon-1 | Theophylline | Interferon alfacon-1 is a recombinant non-naturally occurring type-I interferon. The 166-amino acid sequence of Interferon alfacon-1 was derived by scanning the sequences of several natural interferon alpha subtypes and assigning the most frequently observed amino acid in each corresponding position. Four additional am... | A methylxanthine derivative from tea with diuretic, smooth muscle relaxant, bronchial dilation, cardiac and central nervous system stimulant activities. Mechanistically, theophylline acts as a phosphodiesterase inhibitor, adenosine receptor blocker, and histone deacetylase activator. Theophylline is marketed under seve... | Moderate | 1 | [
[
[
367,
24,
1031
]
],
[
[
367,
24,
1072
],
[
1072,
63,
1031
]
],
[
[
367,
63,
581
],
[
581,
24,
1031
]
],
[
[
367,
25,
1510
],
[
1510,
... | [
[
[
"Interferon alfacon-1",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Theophylline"
]
],
[
[
"Interferon alfacon-1",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Isoni... | Interferon alfacon-1 may cause a moderate interaction that could exacerbate diseases when taken with Isoniazid and Isoniazid may cause a moderate interaction that could exacerbate diseases when taken with Theophylline
Interferon alfacon-1 may cause a moderate interaction that could exacerbate diseases when taken with I... |
DB12130 | DB14975 | 1,017 | 988 | [
"DDInter1094",
"DDInter1949"
] | Lorlatinib | Voxelotor | Lorlatinib is a third-generation ALK tyrosine kinase inhibitor (TKI) for patients with ALK-positive metastatic non-small cell lung cancer which was first approved by the US FDA in November of 2018. It was subsequently approved by the EMA in 2019 for the treatment of select patients with previously treated advanced ALK-... | Voxelotor is a novel hemoglobin S polymerization inhibitor for the treatment of sickle cell disease. This is a genetically inherited condition most prevalent in the Middle East, Africa, and certain parts of India. Sickle cell disease can lead to excruciating pain, stroke, infection, and various other complications aris... | Major | 2 | [
[
[
1017,
25,
988
]
],
[
[
1017,
63,
222
],
[
222,
23,
988
]
],
[
[
1017,
25,
466
],
[
466,
23,
988
]
],
[
[
1017,
63,
251
],
[
251,
... | [
[
[
"Lorlatinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Voxelotor"
]
],
[
[
"Lorlatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sibutramine"
],
[
"Sibutramin... | Lorlatinib may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine and Sibutramine may cause a minor interaction that can limit clinical effects when taken with Voxelotor
Lorlatinib may lead to a major life threatening interaction when taken with Darolutamide and Darolutamide may cau... |
DB00322 | DB08826 | 141 | 1,292 | [
"DDInter742",
"DDInter489"
] | Floxuridine | Deferiprone | An antineoplastic antimetabolite that is metabolized to fluorouracil when administered by rapid injection. Floxuridine is available as a sterile, nonpyrogenic, lyophilized powder for reconstitution. When administered by slow, continuous, intra-arterial infusion, it is converted to floxuridine monophosphate. It has been... | Deferiprone is an oral iron chelator used as a second line agent in thalassemia syndromes when iron overload from blood transfusions occurs. Thalassemias are a type of hereditary anaemia due a defect in the production of hemoglobin. As a result, erythropoiesis, the production of new red blood cells, is impaired. FDA ap... | Major | 2 | [
[
[
141,
25,
1292
]
],
[
[
141,
21,
28809
],
[
28809,
60,
1292
]
],
[
[
141,
24,
482
],
[
482,
25,
1292
]
],
[
[
141,
63,
377
],
[
377,
... | [
[
[
"Floxuridine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Deferiprone"
]
],
[
[
"Floxuridine",
"{u} (Compound) causes {v} (Side Effect)",
"Diarrhoea"
],
[
"Diarrhoea",
"{u} (Side Effect) is caused by {v} (C... | Floxuridine (Compound) causes Diarrhoea (Side Effect) and Diarrhoea (Side Effect) is caused by Deferiprone (Compound)
Floxuridine may cause a moderate interaction that could exacerbate diseases when taken with Tioguanine and Tioguanine may lead to a major life threatening interaction when taken with Deferiprone
Floxuri... |
DB00687 | DB08820 | 870 | 1,478 | [
"DDInter747",
"DDInter997"
] | Fludrocortisone | Ivacaftor | Fludrocortisone is a synthetic mineralocorticoid used in conjunction with [hydrocortisone] to replace missing endogenous corticosteroids in patients with adrenal insufficiency.[A187169,A187187] It is functionally similar to [aldosterone], the body's primary endogenous mineralocorticoid, and is structurally analogous to... | Ivacaftor (also known as Kalydeco or VX-770) is a drug used for the management of Cystic Fibrosis (CF). It is manufactured and distributed by Vertex Pharmaceuticals. It was approved by the Food and Drug Administration on January 31, 2012, and by Health Canada in late 2012. Ivacaftor is administered as a monotherapy and... | Moderate | 1 | [
[
[
870,
24,
1478
]
],
[
[
870,
21,
28762
],
[
28762,
60,
1478
]
],
[
[
870,
23,
307
],
[
307,
23,
1478
]
],
[
[
870,
24,
1411
],
[
1411,
... | [
[
[
"Fludrocortisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ivacaftor"
]
],
[
[
"Fludrocortisone",
"{u} (Compound) causes {v} (Side Effect)",
"Headache"
],
[
"Headache",
"{u} (Side Effect) ... | Fludrocortisone (Compound) causes Headache (Side Effect) and Headache (Side Effect) is caused by Ivacaftor (Compound)
Fludrocortisone may cause a minor interaction that can limit clinical effects when taken with Modafinil and Modafinil may cause a minor interaction that can limit clinical effects when taken with Ivacaf... |
DB04868 | DB14723 | 478 | 159 | [
"DDInter1293",
"DDInter1026"
] | Nilotinib | Larotrectinib | Nilotinib, also known as AMN107, is a tyrosine kinase inhibitor under investigation as a possible treatment for chronic myelogenous leukemia (CML). A Phase I clinical trial in 2006 showed that this drug was relatively safe and offered significant therapeutic benefits in cases of CML which were found to be resistant to ... | Larotrectinib is an orally administered inhibitor of tropomyosin receptor kinase (Trk), a receptor tyrosine kinase activated by neurotrophins which is mutated in a variety of cancer cell types and plays an important role in tumor cell growth and survival. Upon administration, larotrectinib binds to Trk, thereby prevent... | Moderate | 1 | [
[
[
478,
24,
159
]
],
[
[
478,
63,
222
],
[
222,
23,
159
]
],
[
[
478,
23,
907
],
[
907,
23,
159
]
],
[
[
478,
62,
479
],
[
479,
23,... | [
[
[
"Nilotinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Larotrectinib"
]
],
[
[
"Nilotinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sibutramine"
],
[
... | Nilotinib may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine and Sibutramine may cause a minor interaction that can limit clinical effects when taken with Larotrectinib
Nilotinib may cause a minor interaction that can limit clinical effects when taken with Doravirine and Doravir... |
DB09054 | DB09498 | 384 | 810 | [
"DDInter905",
"DDInter1715"
] | Idelalisib | Strontium chloride Sr-89 | Idelalisib is a phosphoinositide 3-kinase inhibitor indicated in the treatment of chronic lymphocytic leukemia (CLL), relapsed follicular B-cell non-Hodgkin lymphoma (FL), and relapsed small lymphocytic lymphoma (SLL). For the treatment of relapsed CLL, it is currently indicated as a second-line agent in combination wi... | Strontium chloride (Sr-89), initially FDA-approved in 1993, is used as a paliative therapeutic option to help relieve the pain from bone metastases. Strontium chloride is mainly used in cases of metastatic castrate-resistant prostate cancer. Bone metastases is a common and severe complication presented in advanced stag... | Moderate | 1 | [
[
[
384,
24,
810
]
],
[
[
384,
63,
552
],
[
552,
24,
810
]
],
[
[
384,
25,
1060
],
[
1060,
63,
810
]
],
[
[
384,
24,
1480
],
[
1480,
... | [
[
[
"Idelalisib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Strontium chloride Sr-89"
]
],
[
[
"Idelalisib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Carmustine"
... | Idelalisib may cause a moderate interaction that could exacerbate diseases when taken with Carmustine and Carmustine may cause a moderate interaction that could exacerbate diseases when taken with Strontium chloride Sr-89
Idelalisib may lead to a major life threatening interaction when taken with Enfortumab vedotin and... |
DB00013 | DB00476 | 1,255 | 109 | [
"DDInter1905",
"DDInter608"
] | Urokinase | Duloxetine | Urokinase is an endogenous peptide that is cleaved in the presence of plasmin between lysine 158 and isoleucine 159 to yield active urokinase. Urokinase remains connected between these 2 chains by a sulfhydryl bond. Urokinase was granted FDA approval on 16 January 1978. | Duloxetine is a dual serotonin and norepinephrine reuptake inhibitor.[label] It was originally discovered in 1993 and developed by Eli Lilly and Company as LY248686. Duloxetine first received approval from the FDA in August, 2004 as Cymbalta for the treatment of Major Depressive Disorder. It has since received approval... | Moderate | 1 | [
[
[
1255,
24,
109
]
],
[
[
1255,
24,
758
],
[
758,
1,
109
]
],
[
[
1255,
25,
1409
],
[
1409,
63,
109
]
],
[
[
1255,
24,
477
],
[
477,
... | [
[
[
"Urokinase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Duloxetine"
]
],
[
[
"Urokinase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fluoxetine"
],
[
... | Urokinase may cause a moderate interaction that could exacerbate diseases when taken with Fluoxetine and Fluoxetine (Compound) resembles Duloxetine (Compound)
Urokinase may lead to a major life threatening interaction when taken with Apixaban and Apixaban may cause a moderate interaction that could exacerbate diseases ... |
DB00352 | DB06616 | 482 | 594 | [
"DDInter1814",
"DDInter224"
] | Tioguanine | Bosutinib | An antineoplastic compound which also has antimetabolite action. The drug is used in the therapy of acute leukemia. | Bosutinib is a 7-alkoxy-3-quinolinecarbonitrile that functions as a potent, dual SRC and ABL tyrosine kinase inhibitor indicated for chronic myelogenous leukemia (CML), specifically Philadelphia chromosome-positive (Ph+) CML. Philadelphia chromosome is a hallmark of CML due to the reciprocal translocation t(9;22)(q34;q... | Moderate | 1 | [
[
[
482,
24,
594
]
],
[
[
482,
63,
883
],
[
883,
1,
594
]
],
[
[
482,
21,
28709
],
[
28709,
60,
594
]
],
[
[
482,
24,
1247
],
[
1247,
... | [
[
[
"Tioguanine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bosutinib"
]
],
[
[
"Tioguanine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gefitinib"
],
[
... | Tioguanine may cause a moderate interaction that could exacerbate diseases when taken with Gefitinib and Gefitinib (Compound) resembles Bosutinib (Compound)
Tioguanine (Compound) causes Decreased appetite (Side Effect) and Decreased appetite (Side Effect) is caused by Bosutinib (Compound)
Tioguanine may cause a moderat... |
DB06603 | DB09020 | 39 | 28 | [
"DDInter1387",
"DDInter212"
] | Panobinostat | Bisacodyl | Panobinostat is an oral deacetylace (DAC) inhibitor approved on February 23, 2015 by the FDA for the treatment of multiple myeloma. The approval was accelerated based on progression-free survival, therefore confirmatory trials by the sponsor to demonstrate clinical efficacy in multiple myeloma treatment are in progress... | Bisacodyl, a diphenylmethane derivative, is a commonly used over the counter stimulant laxative for occasional constipation.[A233300,L13362] Both bisacodyl and [picosulfate] are metabolized to the same active metabolite bis-(p-hydroxyphenyl)-pyridyl-2-methane (BHPM).[A233290,A233300,A207700] Bisacodyl was patented on 2... | Moderate | 1 | [
[
[
39,
24,
28
]
],
[
[
39,
63,
272
],
[
272,
40,
28
]
],
[
[
39,
64,
739
],
[
739,
24,
28
]
],
[
[
39,
25,
938
],
[
938,
63,
... | [
[
[
"Panobinostat",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bisacodyl"
]
],
[
[
"Panobinostat",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chlorpheniramine"
],... | Panobinostat may cause a moderate interaction that could exacerbate diseases when taken with Chlorpheniramine and Chlorpheniramine (Compound) resembles Bisacodyl (Compound)
Panobinostat may lead to a major life threatening interaction when taken with Lomefloxacin and Lomefloxacin may cause a moderate interaction that c... |
DB00477 | DB13928 | 216 | 1,385 | [
"DDInter363",
"DDInter1660"
] | Chlorpromazine | Semaglutide | The prototypical phenothiazine antipsychotic drug. Like the other drugs in this class, chlorpromazine's antipsychotic actions are thought to be due to long-term adaptation by the brain to blocking dopamine receptors. Chlorpromazine has several other actions and therapeutic uses, including as an antiemetic and in the tr... | Semaglutide is a glucagon-like peptide 1 (GLP-1) analog used to manage type 2 diabetes along with lifestyle changes, such as dietary restrictions and increased physical activity.[A31421,L8681] Other members of this drug class include [Exenatide] and [Liraglutide]. Semaglutide was developed by Novo Nordisk and approved ... | Moderate | 1 | [
[
[
216,
24,
1385
]
],
[
[
216,
25,
1154
],
[
1154,
24,
1385
]
],
[
[
216,
63,
73
],
[
73,
24,
1385
]
],
[
[
216,
24,
1144
],
[
1144,
... | [
[
[
"Chlorpromazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Semaglutide"
]
],
[
[
"Chlorpromazine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Pasireotide"
],
[
"... | Chlorpromazine may lead to a major life threatening interaction when taken with Pasireotide and Pasireotide may cause a moderate interaction that could exacerbate diseases when taken with Semaglutide
Chlorpromazine may cause a moderate interaction that could exacerbate diseases when taken with Phentermine and Phentermi... |
DB08816 | DB11986 | 578 | 484 | [
"DDInter1802",
"DDInter648"
] | Ticagrelor | Entrectinib | Ticagrelor, or AZD6140, was first described in the literature in 2003.[A204170,A2903] Ticagrelor is an ADP derivative developed for its P2Y<sub>12</sub> receptor antagonism. Unlike [clopidogrel], ticagrelor is not a prodrug. It is marketed by Astra Zeneca as Brilinta in the US and Brilique or Possia in the EU,. Ticagre... | Entrectinib is a tropomyosin receptor tyrosine kinase (TRK) TRKA, TRKB, TRKC, proto-oncogene tyrosine-protein kinase ROS1, and anaplastic lymphoma kinase (ALK) inhibitor. It was approved by the FDA in August 2019 for use in the treatment of ROS1-positive metastatic non-small cell lung cancer and NTRK gene fusion positi... | Moderate | 1 | [
[
[
578,
24,
484
]
],
[
[
578,
23,
271
],
[
271,
23,
484
]
],
[
[
578,
63,
222
],
[
222,
23,
484
]
],
[
[
578,
23,
907
],
[
907,
62,... | [
[
[
"Ticagrelor",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Entrectinib"
]
],
[
[
"Ticagrelor",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Mirabegron"
],
[
... | Ticagrelor may cause a minor interaction that can limit clinical effects when taken with Mirabegron and Mirabegron may cause a minor interaction that can limit clinical effects when taken with Entrectinib
Ticagrelor may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine and Sibutram... |
DB00242 | DB08899 | 1,064 | 129 | [
"DDInter392",
"DDInter649"
] | Cladribine | Enzalutamide | An antineoplastic agent used in the treatment of lymphoproliferative diseases including hairy-cell leukemia. | Enzalutamide is an androgen receptor (AR) inhibitor for the treatment of castration-resistant prostate cancer (CRPC), both metastatic and non-metastatic. It is a second-generation antiandrogen agent that the FDA approved on August 31, 2012.[L40639, A252667] Although androgen deprivation therapy (ADT) is the first-line ... | Moderate | 1 | [
[
[
1064,
24,
129
]
],
[
[
1064,
7,
5562
],
[
5562,
46,
129
]
],
[
[
1064,
21,
29377
],
[
29377,
60,
129
]
],
[
[
1064,
25,
110
],
[
110,
... | [
[
[
"Cladribine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enzalutamide"
]
],
[
[
"Cladribine",
"{u} (Compound) upregulates {v} (Gene)",
"LOXL1"
],
[
"LOXL1",
"{u} (Gene) is upregulated by {v} ... | Cladribine (Compound) upregulates LOXL1 (Gene) and LOXL1 (Gene) is upregulated by Enzalutamide (Compound)
Cladribine (Compound) causes Musculoskeletal pain (Side Effect) and Musculoskeletal pain (Side Effect) is caused by Enzalutamide (Compound)
Cladribine may lead to a major life threatening interaction when taken wit... |
DB08901 | DB11691 | 1,468 | 1,499 | [
"DDInter1492",
"DDInter1258"
] | Ponatinib | Naldemedine | Ponatinib is a novel Bcr-Abl tyrosine kinase inhibitor that is especially effective against the T315I mutation for the treatment of chronic myeloid leukemia. FDA approved on December 14, 2012. | Naldemedine is an opioid receptor antagonist [FDA Label]. It is a modified form of to which a side chain has been added to increase molecular weight and polar surface area resulting in restricted transport across the blood brain barrier. Naldemedine was approved in 2017 in both the US and Japan for the treatment of Opi... | Moderate | 1 | [
[
[
1468,
24,
1499
]
],
[
[
1468,
62,
307
],
[
307,
23,
1499
]
],
[
[
1468,
63,
932
],
[
932,
24,
1499
]
],
[
[
1468,
74,
1419
],
[
1419,
... | [
[
[
"Ponatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Naldemedine"
]
],
[
[
"Ponatinib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Modafinil"
],
[
... | Ponatinib may cause a minor interaction that can limit clinical effects when taken with Modafinil and Modafinil may cause a minor interaction that can limit clinical effects when taken with Naldemedine
Ponatinib may cause a moderate interaction that could exacerbate diseases when taken with Mifepristone and Mifepriston... |
DB01612 | DB14509 | 1,637 | 1,399 | [
"DDInter92",
"DDInter1081"
] | Amyl Nitrite | Lithium carbonate | Amyl Nitrite is an antihypertensive medicine. Amyl nitrite is employed medically to treat heart diseases such as angina and to treat cyanide poisoning. Its use as a prescription medicine comes from its ability to lower blood pressure. As an inhalant, it also has psychoactive effect which has led to illegal drug use. | Lithium has been used to treat manic episodes since the 19th century. Though it is widely used, its mechanism of action is still unknown[FDA Label][A14585,A176642,A176651,L5843]. Lithium carbonate has a narrow therapeutic range and so careful monitoring is required to avoid adverse effects[FDA Label]. | Moderate | 1 | [
[
[
1637,
24,
1399
]
],
[
[
1637,
63,
820
],
[
820,
24,
1399
]
],
[
[
1637,
24,
407
],
[
407,
24,
1399
]
],
[
[
1637,
63,
593
],
[
593,
... | [
[
[
"Amyl Nitrite",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lithium carbonate"
]
],
[
[
"Amyl Nitrite",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alimemazine"
... | Amyl Nitrite may cause a moderate interaction that could exacerbate diseases when taken with Alimemazine and Alimemazine may cause a moderate interaction that could exacerbate diseases when taken with Lithium carbonate
Amyl Nitrite may cause a moderate interaction that could exacerbate diseases when taken with Opium an... |
DB06335 | DB06636 | 761 | 1,623 | [
"DDInter1646",
"DDInter980"
] | Saxagliptin | Isavuconazonium | Saxagliptin (rINN) is an orally active hypoglycemic (anti-diabetic drug) of the new dipeptidyl peptidase-4 (DPP-4) inhibitor class of drugs. FDA approved on July 31, 2009. | Isavuconazonium is a second-generation triazole antifungal approved on March 6, 2015 by the FDA and July 2015 by the EMA for the treatment of adults with invasive aspergillosis and invasive mucormycosis, marketed by Astellas under the brand Cresemba. It is the prodrug form of isavuconazole, the active moiety, and it is... | Moderate | 1 | [
[
[
761,
24,
1623
]
],
[
[
761,
63,
222
],
[
222,
23,
1623
]
],
[
[
761,
63,
1419
],
[
1419,
24,
1623
]
],
[
[
761,
24,
1593
],
[
1593,
... | [
[
[
"Saxagliptin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Isavuconazonium"
]
],
[
[
"Saxagliptin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sibutramine"
],
... | Saxagliptin may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine and Sibutramine may cause a minor interaction that can limit clinical effects when taken with Isavuconazonium
Saxagliptin may cause a moderate interaction that could exacerbate diseases when taken with Imatinib and I... |
DB00159 | DB01088 | 940 | 714 | [
"DDInter903",
"DDInter908"
] | Icosapent | Iloprost | Important polyunsaturated fatty acid found in fish oils. It serves as the precursor for the prostaglandin-3 and thromboxane-3 families. A diet rich in eicosapentaenoic acid lowers serum lipid concentration, reduces incidence of cardiovascular disorders, prevents platelet aggregation, and inhibits arachidonic acid conve... | Iloprost is a mimetic of prostacyclin (PGI2; epoprostenol). Iloprost consists of a mixture of the 4R and 4S diastereoisomers at a ratio of approximately 53:47. It is a potent vasodilator with reported anti-thrombotic properties. | Moderate | 1 | [
[
[
940,
24,
714
]
],
[
[
940,
24,
1479
],
[
1479,
24,
714
]
],
[
[
940,
63,
1432
],
[
1432,
24,
714
]
],
[
[
940,
24,
1564
],
[
1564,
... | [
[
[
"Icosapent",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iloprost"
]
],
[
[
"Icosapent",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acetylsalicylic acid"
],
... | Icosapent may cause a moderate interaction that could exacerbate diseases when taken with Acetylsalicylic acid and Acetylsalicylic acid may cause a moderate interaction that could exacerbate diseases when taken with Iloprost
Icosapent may cause a moderate interaction that could exacerbate diseases when taken with Abcix... |
DB12015 | DB12457 | 1,033 | 1,180 | [
"DDInter53",
"DDInter1598"
] | Alpelisib | Rimegepant | Alpelisib is a phosphatidylinositol 3-kinase (PI3K) inhibitor with potent antitumor activity. It works by selectively inhibiting class I PI3K p110α, which is the catalytic subunit of PI3K, a lipid kinase that plays a role in various biological processes, including proliferation, survival, differentiation, and metabolis... | Rimegepant is an oral antagonist of the CGRP receptor developed by Biohaven Pharmaceuticals. It received FDA approval on February 27, 2020 for the acute treatment migraine headache, and was subsequently approved by the European Commission in April 2022 for both the treatment and prevention of migraines. While several p... | Moderate | 1 | [
[
[
1033,
24,
1180
]
],
[
[
1033,
63,
741
],
[
741,
24,
1180
]
],
[
[
1033,
24,
1619
],
[
1619,
24,
1180
]
],
[
[
1033,
24,
1501
],
[
1501... | [
[
[
"Alpelisib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rimegepant"
]
],
[
[
"Alpelisib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rolapitant"
],
[
... | Alpelisib may cause a moderate interaction that could exacerbate diseases when taken with Rolapitant and Rolapitant may cause a moderate interaction that could exacerbate diseases when taken with Rimegepant
Alpelisib may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib and Rucaparib... |
DB00951 | DB11730 | 1,072 | 351 | [
"DDInter986",
"DDInter1588"
] | Isoniazid | Ribociclib | Antibacterial agent used primarily as a tuberculostatic. It remains the treatment of choice for tuberculosis. | Ribociclib is a selective cyclin-dependent kinase inhibitor, a class of drugs that help slow the progression of cancer by inhibiting two proteins called cyclin-dependent kinase 4 and 6 (CDK4/6). These proteins, when over-activated, can enable cancer cells to grow and divide too quickly. Targeting CDK4/6 with enhanced p... | Moderate | 1 | [
[
[
1072,
24,
351
]
],
[
[
1072,
63,
112
],
[
112,
23,
351
]
],
[
[
1072,
24,
283
],
[
283,
62,
351
]
],
[
[
1072,
24,
310
],
[
310,
... | [
[
[
"Isoniazid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ribociclib"
]
],
[
[
"Isoniazid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metronidazole"
],
[
... | Isoniazid may cause a moderate interaction that could exacerbate diseases when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Ribociclib
Isoniazid may cause a moderate interaction that could exacerbate diseases when taken with Fedratinib and Fedr... |
DB10316 | DB12159 | 334 | 12 | [
"DDInter1248",
"DDInter609"
] | Mumps virus strain B level jeryl lynn live antigen | Dupilumab | Mumps virus strain B level jeryl lynn live antigen is a live attenuated virus vaccine for subcutenous injection. It is an active immunization against mumps, which is a common childhood disease. | Dupilumab is a fully human monoclonal antibody of the immunoglobulin G4 subclass that binds to the interleukin-4 (IL-4) receptor, inhibiting the receptor signaling pathways. As an interleukin-4 receptor alpha antagonist, dupilumab inhibits the signaling of pro-inflammatory cytokines, called interleukins (IL), that indu... | Major | 2 | [
[
[
334,
25,
12
]
],
[
[
334,
64,
599
],
[
599,
24,
12
]
],
[
[
334,
64,
1011
],
[
1011,
25,
12
]
],
[
[
334,
25,
676
],
[
676,
64,
... | [
[
[
"Mumps virus strain B level jeryl lynn live antigen",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dupilumab"
]
],
[
[
"Mumps virus strain B level jeryl lynn live antigen",
"{u} may lead to a major life threatening interaction when ta... | Mumps virus strain B level jeryl lynn live antigen may lead to a major life threatening interaction when taken with Alemtuzumab and Alemtuzumab may cause a moderate interaction that could exacerbate diseases when taken with Dupilumab
Mumps virus strain B level jeryl lynn live antigen may lead to a major life threatenin... |
DB00674 | DB01206 | 1,516 | 37 | [
"DDInter802",
"DDInter1086"
] | Galantamine | Lomustine | Galantamine is a tertiary alkaloid and reversible, competitive inhibitor of the acetylcholinesterase (AChE) enzyme, which is a widely studied therapeutic target used in the treatment of Alzheimer's disease. First characterized in the early 1950s, galantamine is a tertiary alkaloid that was extracted from botanical sour... | An alkylating agent of value against both hematologic malignancies and solid tumors. | Moderate | 1 | [
[
[
1516,
24,
37
]
],
[
[
1516,
6,
8374
],
[
8374,
45,
37
]
],
[
[
1516,
21,
28675
],
[
28675,
60,
37
]
],
[
[
1516,
24,
51
],
[
51,
... | [
[
[
"Galantamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lomustine"
]
],
[
[
"Galantamine",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)"... | Galantamine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Lomustine (Compound)
Galantamine (Compound) causes Visual impairment (Side Effect) and Visual impairment (Side Effect) is caused by Lomustine (Compound)
Galantamine may cause a moderate interaction that could exacerbate diseases when taken with Da... |
DB01132 | DB04868 | 1,130 | 478 | [
"DDInter1472",
"DDInter1293"
] | Pioglitazone | Nilotinib | Pioglitazone is an antihyperglycemic used as an adjunct to diet, exercise, and other antidiabetic medications to manage type 2 diabetes mellitus.[L11416,L11419,L11422,L11425] It is administered as a racemic mixture, though there is no pharmacologic difference between the enantiomers and they appear to interconvert _in ... | Nilotinib, also known as AMN107, is a tyrosine kinase inhibitor under investigation as a possible treatment for chronic myelogenous leukemia (CML). A Phase I clinical trial in 2006 showed that this drug was relatively safe and offered significant therapeutic benefits in cases of CML which were found to be resistant to ... | Moderate | 1 | [
[
[
1130,
24,
478
]
],
[
[
1130,
6,
6017
],
[
6017,
45,
478
]
],
[
[
1130,
7,
5057
],
[
5057,
46,
478
]
],
[
[
1130,
21,
28762
],
[
28762,... | [
[
[
"Pioglitazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nilotinib"
]
],
[
[
"Pioglitazone",
"{u} (Compound) binds {v} (Gene)",
"CYP2C9"
],
[
"CYP2C9",
"{u} (Gene) is bound by {v} (Compound... | Pioglitazone (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Nilotinib (Compound)
Pioglitazone (Compound) upregulates IL1B (Gene) and IL1B (Gene) is upregulated by Nilotinib (Compound)
Pioglitazone (Compound) causes Headache (Side Effect) and Headache (Side Effect) is caused by Nilotinib (Compound)
Pioglit... |
DB00631 | DB00879 | 372 | 1,279 | [
"DDInter405",
"DDInter637"
] | Clofarabine | Emtricitabine | Clofarabine is a purine nucleoside antimetabolite that is being studied in the treatment of cancer. It is marketed as Clolar in the U.S. and Canada, or Evoltra in Europe, Australia, and New Zealand. Clofarabine is used in paediatrics to treat a type of leukaemia called relapsed or refractory acute lymphoblastic leukaem... | Emtricitabine is a nucleoside reverse transcriptase inhibitor (NRTI) indicated for the treatment of HIV infection in adults or combined with [tenofovir alafenamide] for the prevention of HIV-1 infection in high risk adolescents and adults. Emtricitabine is a cytidine analogue. The drug works by inhibiting HIV reverse t... | Moderate | 1 | [
[
[
372,
24,
1279
]
],
[
[
372,
1,
903
],
[
903,
40,
1279
]
],
[
[
372,
63,
141
],
[
141,
40,
1279
]
],
[
[
372,
6,
6248
],
[
6248,
... | [
[
[
"Clofarabine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Emtricitabine"
]
],
[
[
"Clofarabine",
"{u} (Compound) resembles {v} (Compound)",
"Decitabine"
],
[
"Decitabine",
"{u} (Compound) res... | Clofarabine (Compound) resembles Decitabine (Compound) and Decitabine (Compound) resembles Emtricitabine (Compound)
Clofarabine may cause a moderate interaction that could exacerbate diseases when taken with Floxuridine and Floxuridine (Compound) resembles Emtricitabine (Compound)
Clofarabine (Compound) binds DCK (Gene... |
DB00284 | DB02546 | 1,647 | 137 | [
"DDInter11",
"DDInter1947"
] | Acarbose | Vorinostat | Acarbose is a complex oligosaccharide that acts as an inhibitor of several enzymes responsible for the breakdown of complex carbohydrates in the intestines. It inhibits both pancreatic alpha-amylase and membrane-bound alpha-glucosidases - including intestinal glucoamylase, sucrase, maltase, and isomaltase - which are r... | Vorinostat (rINN) or suberoylanilide hydroxamic acid (SAHA), is a drug currently under investigation for the treatment of cutaneous T cell lymphoma (CTCL), a type of skin cancer, to be used when the disease persists, gets worse, or comes back during or after treatment with other medicines. It is the first in a new clas... | Moderate | 1 | [
[
[
1647,
24,
137
]
],
[
[
1647,
21,
29519
],
[
29519,
60,
137
]
],
[
[
1647,
23,
135
],
[
135,
63,
137
]
],
[
[
1647,
23,
1645
],
[
1645,... | [
[
[
"Acarbose",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vorinostat"
]
],
[
[
"Acarbose",
"{u} (Compound) causes {v} (Side Effect)",
"Gastrointestinal symptom NOS"
],
[
"Gastrointestinal symptom NOS"... | Acarbose (Compound) causes Gastrointestinal symptom NOS (Side Effect) and Gastrointestinal symptom NOS (Side Effect) is caused by Vorinostat (Compound)
Acarbose may cause a minor interaction that can limit clinical effects when taken with Albiglutide and Albiglutide may cause a moderate interaction that could exacerbat... |
DB01174 | DB06603 | 697 | 39 | [
"DDInter1442",
"DDInter1387"
] | Phenobarbital | Panobinostat | A barbituric acid derivative that acts as a nonselective central nervous system depressant. It promotes binding to inhibitory gamma-aminobutyric acid subtype receptors, and modulates chloride currents through receptor channels. It also inhibits glutamate induced depolarizations. | Panobinostat is an oral deacetylace (DAC) inhibitor approved on February 23, 2015 by the FDA for the treatment of multiple myeloma. The approval was accelerated based on progression-free survival, therefore confirmatory trials by the sponsor to demonstrate clinical efficacy in multiple myeloma treatment are in progress... | Major | 2 | [
[
[
697,
25,
39
]
],
[
[
697,
63,
112
],
[
112,
23,
39
]
],
[
[
697,
63,
272
],
[
272,
24,
39
]
],
[
[
697,
24,
1683
],
[
1683,
24,
... | [
[
[
"Phenobarbital",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Panobinostat"
]
],
[
[
"Phenobarbital",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metronidazole"
],
[
... | Phenobarbital may cause a moderate interaction that could exacerbate diseases when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Panobinostat
Phenobarbital may cause a moderate interaction that could exacerbate diseases when taken with Chlorphen... |
DB00063 | DB00159 | 366 | 940 | [
"DDInter659",
"DDInter903"
] | Eptifibatide | Icosapent | Synthetic cyclic hexapeptide that binds to platelet receptor glycoprotein and inhibits platelet aggregation. Derived from venom of the Southeastern pygmy rattlesnake (Sistrurus miliarus barbouri), eptifibatide is a cyclic heptapeptide that belongs to the class of arginin-glycin-aspartat-mimetics. | Important polyunsaturated fatty acid found in fish oils. It serves as the precursor for the prostaglandin-3 and thromboxane-3 families. A diet rich in eicosapentaenoic acid lowers serum lipid concentration, reduces incidence of cardiovascular disorders, prevents platelet aggregation, and inhibits arachidonic acid conve... | Moderate | 1 | [
[
[
366,
24,
940
]
],
[
[
366,
25,
500
],
[
500,
63,
940
]
],
[
[
366,
64,
582
],
[
582,
24,
940
]
],
[
[
366,
24,
1061
],
[
1061,
6... | [
[
[
"Eptifibatide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Icosapent"
]
],
[
[
"Eptifibatide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Enoxaparin"
],
[
"Enoxapa... | Eptifibatide may lead to a major life threatening interaction when taken with Enoxaparin and Enoxaparin may cause a moderate interaction that could exacerbate diseases when taken with Icosapent
Eptifibatide may lead to a major life threatening interaction when taken with Reteplase and Reteplase may cause a moderate int... |
DB01309 | DB09043 | 1,254 | 135 | [
"DDInter933",
"DDInter36"
] | Insulin glulisine | Albiglutide | Insulin glulisine is a short-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes. Insulin is typically prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide hormone produced by beta cells of the pancreas... | Albiglutide is a glucagon-like peptide-1 agonist (GLP-1) biologic drug indicated in the treatment of type 2 diabetes. It is marketed under the brands Eperzan and Tanzeum by GSK (GlaxoSmithKline). It is a dipeptidyl peptidase-4-resistant glucagon-like peptide-1 dimer fused to human albumin. Albiglutide was approved on A... | Moderate | 1 | [
[
[
1254,
24,
135
]
],
[
[
1254,
62,
1103
],
[
1103,
23,
135
]
],
[
[
1254,
24,
624
],
[
624,
24,
135
]
],
[
[
1254,
63,
519
],
[
519,
... | [
[
[
"Insulin glulisine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Albiglutide"
]
],
[
[
"Insulin glulisine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Amcinonide"
... | Insulin glulisine may cause a minor interaction that can limit clinical effects when taken with Amcinonide and Amcinonide may cause a minor interaction that can limit clinical effects when taken with Albiglutide
Insulin glulisine may cause a moderate interaction that could exacerbate diseases when taken with Liotrix an... |
DB00363 | DB08880 | 695 | 1,510 | [
"DDInter419",
"DDInter1771"
] | Clozapine | Teriflunomide | Clozapine is a tricyclic dibenzodiazepine, classified as an atypical antipsychotic agent. Clozapine displays affinity to various neuroreceptors with a particularly low affinity to the dopamine receptors, thus breaking the mold of first-generation antipsychotics and deeming it "atypical".. This low affinity to dopamine ... | Teriflunomide is the active metabolite of leflunomide, and it acts as an immunomodulatory agent by inhibiting pyrimidine synthesis. It is marketed under the name Aubagio® and is indicated for the treatment of multiple sclerosis, specifically relapsing forms. The FDA label states an important warning about the risk of h... | Major | 2 | [
[
[
695,
25,
1510
]
],
[
[
695,
25,
129
],
[
129,
63,
1510
]
],
[
[
695,
24,
1144
],
[
1144,
24,
1510
]
],
[
[
695,
24,
741
],
[
741,
... | [
[
[
"Clozapine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Teriflunomide"
]
],
[
[
"Clozapine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Enzalutamide"
],
[
"Enzalutamide",
"... | Clozapine may lead to a major life threatening interaction when taken with Enzalutamide and Enzalutamide may cause a moderate interaction that could exacerbate diseases when taken with Teriflunomide
Clozapine may cause a moderate interaction that could exacerbate diseases when taken with Nateglinide and Nateglinide may... |
DB00014 | DB00450 | 521 | 78 | [
"DDInter839",
"DDInter603"
] | Goserelin | Droperidol | Goserelin is a synthetic hormone. In men, it stops the production of the hormone testosterone, which may stimulate the growth of cancer cells. In women, goserelin decreases the production of the hormone estradiol (which may stimulate the growth of cancer cells) to levels similar to a postmenopausal state. When the medi... | A butyrophenone with general properties similar to those of haloperidol. It is used in conjunction with an opioid analgesic such as fentanyl to maintain the patient in a calm state of neuroleptanalgesia with indifference to surroundings but still able to cooperate with the surgeon. It is also used as a premedicant, as ... | Major | 2 | [
[
[
521,
25,
78
]
],
[
[
521,
25,
1300
],
[
1300,
40,
78
]
],
[
[
521,
25,
1568
],
[
1568,
1,
78
]
],
[
[
521,
21,
28921
],
[
28921,
... | [
[
[
"Goserelin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Droperidol"
]
],
[
[
"Goserelin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Haloperidol"
],
[
"Haloperidol",
"{u} (... | Goserelin may lead to a major life threatening interaction when taken with Haloperidol and Haloperidol (Compound) resembles Droperidol (Compound)
Goserelin may lead to a major life threatening interaction when taken with Pimozide and Pimozide (Compound) resembles Droperidol (Compound)
Goserelin (Compound) causes Dizzin... |
DB00916 | DB01394 | 112 | 1,554 | [
"DDInter1202",
"DDInter431"
] | Metronidazole | Colchicine | Metronidazole is a commonly used antibiotic, belonging to the nitroimidazole class of antibiotics. It is frequently used to treat gastrointestinal infections as well as trichomoniasis and giardiasis, and amebiasis which are parasitic infections.[A181036,A181039] Metronidazole has been used as an antibiotic for several ... | Colchicine is an alkaloid drug derived from a plant belonging to the Lily family, known as _Colchicum autumnale_, or "autumn crocus." Its use was first approved by the FDA in 1961. Colchicine is used in the treatment of gout flares and Familial Mediterranean fever, and prevention of major cardiovascular events. It has ... | Moderate | 1 | [
[
[
112,
24,
1554
]
],
[
[
112,
6,
3486
],
[
3486,
45,
1554
]
],
[
[
112,
21,
28714
],
[
28714,
60,
1554
]
],
[
[
112,
63,
367
],
[
367,
... | [
[
[
"Metronidazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Colchicine"
]
],
[
[
"Metronidazole",
"{u} (Compound) binds {v} (Gene)",
"CYP2C8"
],
[
"CYP2C8",
"{u} (Gene) is bound by {v} (Compo... | Metronidazole (Compound) binds CYP2C8 (Gene) and CYP2C8 (Gene) is bound by Colchicine (Compound)
Metronidazole (Compound) causes Asthenia (Side Effect) and Asthenia (Side Effect) is caused by Colchicine (Compound)
Metronidazole may cause a moderate interaction that could exacerbate diseases when taken with Interferon a... |
DB00242 | DB11796 | 1,064 | 1,612 | [
"DDInter392",
"DDInter786"
] | Cladribine | Fostemsavir | An antineoplastic agent used in the treatment of lymphoproliferative diseases including hairy-cell leukemia. | Fostemsavir is the phosphonooxymethyl prodrug of temsavir, a novel HIV-1 attachment inhibitor. It binds to and inhibits the activity of gp120, a subunit within the HIV-1 gp160 envelope glycoprotein that facilitates the attachment of HIV-1 to host cell CD4 receptors - in doing so, temsavir prevents the first step in the... | Moderate | 1 | [
[
[
1064,
24,
1612
]
],
[
[
1064,
25,
1476
],
[
1476,
62,
1612
]
],
[
[
1064,
25,
1101
],
[
1101,
23,
1612
]
],
[
[
1064,
24,
1017
],
[
10... | [
[
[
"Cladribine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fostemsavir"
]
],
[
[
"Cladribine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Brigatinib"
],
[
"Brigatini... | Cladribine may lead to a major life threatening interaction when taken with Brigatinib and Brigatinib may cause a minor interaction that can limit clinical effects when taken with Fostemsavir
Cladribine may lead to a major life threatening interaction when taken with Bexarotene and Bexarotene may cause a minor interact... |
DB00959 | DB01359 | 1,486 | 729 | [
"DDInter1191",
"DDInter1417"
] | Methylprednisolone | Penbutolol | Methylprednisolone is a [prednisolone] derivative glucocorticoid with higher potency than [prednisone]. It was first described in the literature in the late 1950s.[A188811,A188814] Methylprednisolone was granted FDA approval on 24 October 1957. In the outbreak of COVID-19, low dose methylprednisolone-based therapy was ... | Penbutolol is a drug in the beta-blocker class used to treat hypertension. Penbutolol binds both beta-1 and beta-2 adrenergic receptors, rendering it a non-selective beta-blocker. Penbutolol can act as a partial agonist at beta adrenergic receptors, since it is a sympathomimetric drug. Penbutolol also demonstrates high... | Moderate | 1 | [
[
[
1486,
24,
729
]
],
[
[
1486,
63,
461
],
[
461,
1,
729
]
],
[
[
1486,
24,
699
],
[
699,
40,
729
]
],
[
[
1486,
21,
28698
],
[
28698,
... | [
[
[
"Methylprednisolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Penbutolol"
]
],
[
[
"Methylprednisolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Timolol"
... | Methylprednisolone may cause a moderate interaction that could exacerbate diseases when taken with Timolol and Timolol (Compound) resembles Penbutolol (Compound)
Methylprednisolone may cause a moderate interaction that could exacerbate diseases when taken with Nadolol and Nadolol (Compound) resembles Penbutolol (Compou... |
DB04855 | DB06595 | 540 | 1,491 | [
"DDInter602",
"DDInter1214"
] | Dronedarone | Midostaurin | Dronedarone is a Class III antiarrhythmic drug that works to restore the normal sinus rhythm in patients with paroxysmal or persistent atrial fibrillation. Atrial fibrillation is a common sustained arrhythmia where the treatment primarily focuses on stroke prevention and symptom management. It is managed by rate contro... | Midostaurin (as Rydapt) is a multitarget kinase inhibitor for the treatment for adult patients with newly diagnosed acute myeloid leukemia (AML) who have a specific genetic mutation called FLT3. It was initially characterized as a potential broad-spectrum antineoplastic agent, with activity toward diverse solid and hem... | Major | 2 | [
[
[
540,
25,
1491
]
],
[
[
540,
25,
1135
],
[
1135,
62,
1491
]
],
[
[
540,
62,
112
],
[
112,
23,
1491
]
],
[
[
540,
24,
761
],
[
761,
... | [
[
[
"Dronedarone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Midostaurin"
]
],
[
[
"Dronedarone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Naloxegol"
],
[
"Naloxegol",
"{u} ... | Dronedarone may lead to a major life threatening interaction when taken with Naloxegol and Naloxegol may cause a minor interaction that can limit clinical effects when taken with Midostaurin
Dronedarone may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cau... |
DB08826 | DB12887 | 1,292 | 1,598 | [
"DDInter489",
"DDInter1750"
] | Deferiprone | Tazemetostat | Deferiprone is an oral iron chelator used as a second line agent in thalassemia syndromes when iron overload from blood transfusions occurs. Thalassemias are a type of hereditary anaemia due a defect in the production of hemoglobin. As a result, erythropoiesis, the production of new red blood cells, is impaired. FDA ap... | Tazemetostat is a methyltransferase inhibitor used to treat metastatic or locally advanced epithelioid sarcoma not eligible for complete resection. Tazemetostat was first named in literature as EPZ-6438. Tazemetaostat was granted FDA approval on 23 January 2020. | Major | 2 | [
[
[
1292,
25,
1598
]
],
[
[
1292,
64,
168
],
[
168,
23,
1598
]
],
[
[
1292,
64,
594
],
[
594,
24,
1598
]
],
[
[
1292,
25,
985
],
[
985,
... | [
[
[
"Deferiprone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tazemetostat"
]
],
[
[
"Deferiprone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bortezomib"
],
[
"Bortezomib",
"{... | Deferiprone may lead to a major life threatening interaction when taken with Bortezomib and Bortezomib may cause a minor interaction that can limit clinical effects when taken with Tazemetostat
Deferiprone may lead to a major life threatening interaction when taken with Bosutinib and Bosutinib may cause a moderate inte... |
DB00687 | DB01018 | 870 | 1,364 | [
"DDInter747",
"DDInter847"
] | Fludrocortisone | Guanfacine | Fludrocortisone is a synthetic mineralocorticoid used in conjunction with [hydrocortisone] to replace missing endogenous corticosteroids in patients with adrenal insufficiency.[A187169,A187187] It is functionally similar to [aldosterone], the body's primary endogenous mineralocorticoid, and is structurally analogous to... | Guanfacine, or BS 100-141,[A189838,A189841] is a selective alpha-A2 adrenergic receptor agonist initially indicated for the treatment of hypertension but is now indicated as an extended release tablet for the treatment of ADHD. Guanfacine was first described in the literature in 1974. Guanfacine was granted FDA approva... | Moderate | 1 | [
[
[
870,
24,
1364
]
],
[
[
870,
63,
1512
],
[
1512,
1,
1364
]
],
[
[
870,
21,
28996
],
[
28996,
60,
1364
]
],
[
[
870,
1,
167
],
[
167,
... | [
[
[
"Fludrocortisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Guanfacine"
]
],
[
[
"Fludrocortisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diclofenac"
]... | Fludrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Diclofenac and Diclofenac (Compound) resembles Guanfacine (Compound)
Fludrocortisone (Compound) causes Musculoskeletal discomfort (Side Effect) and Musculoskeletal discomfort (Side Effect) is caused by Guanfacine (Compound)
... |
DB00357 | DB00425 | 1,051 | 558 | [
"DDInter71",
"DDInter1970"
] | Aminoglutethimide | Zolpidem | An aromatase inhibitor that produces a state of "medical" adrenalectomy by blocking the production of adrenal steroids. It also blocks the conversion of androgens to estrogens. Aminoglutethimide has been used in the treatment of advanced breast and prostate cancer. It was formerly used for its weak anticonvulsant prope... | Zolpidem, also known as _Ambien_, is a hypnotic drug that was initially approved by the FDA in 1992 [FDA label]. Zolpidem improves sleep in patients with insomnia. It is aimed for use in patients with difficulties initiating sleep. This drug decreases the time to fall asleep (sleep latency), increases the duration of s... | Moderate | 1 | [
[
[
1051,
24,
558
]
],
[
[
1051,
6,
8374
],
[
8374,
45,
558
]
],
[
[
1051,
21,
28803
],
[
28803,
60,
558
]
],
[
[
1051,
24,
868
],
[
868,
... | [
[
[
"Aminoglutethimide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Zolpidem"
]
],
[
[
"Aminoglutethimide",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} ... | Aminoglutethimide (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Zolpidem (Compound)
Aminoglutethimide (Compound) causes Anaemia (Side Effect) and Anaemia (Side Effect) is caused by Zolpidem (Compound)
Aminoglutethimide may cause a moderate interaction that could exacerbate diseases when taken with Vemura... |
DB00283 | DB00543 | 701 | 87 | [
"DDInter395",
"DDInter82"
] | Clemastine | Amoxapine | An ethanolamine-derivative, first generation histamine H1 antagonist used in hay fever, rhinitis, allergic skin conditions, and pruritus. It causes drowsiness. | Amoxapine, the <i>N</i>-demethylated derivative of the antipsychotic agent loxapine, is a dibenzoxazepine-derivative tricyclic antidepressant (TCA). TCAs are structurally similar to phenothiazines. They contain a tricyclic ring system with an alkyl amine substituent on the central ring. In non-depressed individuals, am... | Moderate | 1 | [
[
[
701,
24,
87
]
],
[
[
701,
24,
1119
],
[
1119,
1,
87
]
],
[
[
701,
63,
905
],
[
905,
40,
87
]
],
[
[
701,
63,
1174
],
[
1174,
1,
... | [
[
[
"Clemastine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Amoxapine"
]
],
[
[
"Clemastine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chlordiazepoxide"
],
... | Clemastine may cause a moderate interaction that could exacerbate diseases when taken with Chlordiazepoxide and Chlordiazepoxide (Compound) resembles Amoxapine (Compound)
Clemastine may cause a moderate interaction that could exacerbate diseases when taken with Lorazepam and Lorazepam (Compound) resembles Amoxapine (Co... |
DB06077 | DB09078 | 879 | 1,228 | [
"DDInter1102",
"DDInter1036"
] | Lumateperone | Lenvatinib | Schizophrenia is a complex mental illness and impacts approximately 1% of the population. Although there are several antipsychotics including [aripiprazole], [paliperidone] and [clozapine] available for clinical use, they are generally accompanied by significant metabolic and/or neurological adverse effects. Lumatepero... | Lenvatinib is a receptor tyrosine kinase (RTK) inhibitor that inhibits the kinase activities of vascular endothelial growth factor (VEGF) receptors VEGFR1 (FLT1), VEGFR2 (KDR), and VEGFR3 (FLT4). Lenvatinib also inhibits other RTKs that have been implicated in pathogenic angiogenesis, tumor growth, and cancer progressi... | Moderate | 1 | [
[
[
879,
24,
1228
]
],
[
[
879,
64,
609
],
[
609,
24,
1228
]
],
[
[
879,
63,
1264
],
[
1264,
24,
1228
]
],
[
[
879,
25,
384
],
[
384,
... | [
[
[
"Lumateperone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lenvatinib"
]
],
[
[
"Lumateperone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Clarithromycin"
],
[
"Cl... | Lumateperone may lead to a major life threatening interaction when taken with Clarithromycin and Clarithromycin may cause a moderate interaction that could exacerbate diseases when taken with Lenvatinib
Lumateperone may cause a moderate interaction that could exacerbate diseases when taken with Doxepin and Doxepin may ... |
DB00059 | DB00881 | 1,560 | 954 | [
"DDInter1404",
"DDInter1554"
] | Pegaspargase | Quinapril | Pegaspargase is a conjugate of monomethoxypolyethylene glycol (mPEG) and L-asparaginase (L-asparagine amidohydrolase), an asparagine-specific enzyme that converts L-asparagine into aspartic acid and ammonia. Asparagine is an amino acid that is vital for cell survival. In humans, most normal tissues can produce asparagi... | Quinapril is the ethyl ester prodrug of the non-sulfhydryl angiotensin converting enzyme inhibitor quinaprilat.[L8420,L8423] It is used to treat hypertension and heart failure.[L8420,L8423] ACE inhibitors are commonly used as a first line therapy in the treatment of hypertension, along with thiazide diuretics or beta b... | Moderate | 1 | [
[
[
1560,
24,
954
]
],
[
[
1560,
24,
1638
],
[
1638,
1,
954
]
],
[
[
1560,
24,
1523
],
[
1523,
40,
954
]
],
[
[
1560,
24,
365
],
[
365,
... | [
[
[
"Pegaspargase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Quinapril"
]
],
[
[
"Pegaspargase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trandolapril"
],
... | Pegaspargase may cause a moderate interaction that could exacerbate diseases when taken with Trandolapril and Trandolapril (Compound) resembles Quinapril (Compound)
Pegaspargase may cause a moderate interaction that could exacerbate diseases when taken with Labetalol and Labetalol (Compound) resembles Quinapril (Compou... |
DB11575 | DB11986 | 1,676 | 484 | [
"DDInter841",
"DDInter648"
] | Grazoprevir | Entrectinib | Grazoprevir is a direct acting antiviral medication used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV). HCV is a single-stranded RNA virus that is categorized into nine distinct genotypes, with genotype 1 being the most common i... | Entrectinib is a tropomyosin receptor tyrosine kinase (TRK) TRKA, TRKB, TRKC, proto-oncogene tyrosine-protein kinase ROS1, and anaplastic lymphoma kinase (ALK) inhibitor. It was approved by the FDA in August 2019 for use in the treatment of ROS1-positive metastatic non-small cell lung cancer and NTRK gene fusion positi... | Moderate | 1 | [
[
[
1676,
24,
484
]
],
[
[
1676,
25,
466
],
[
466,
62,
484
]
],
[
[
1676,
64,
467
],
[
467,
24,
484
]
],
[
[
1676,
63,
1478
],
[
1478,
... | [
[
[
"Grazoprevir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Entrectinib"
]
],
[
[
"Grazoprevir",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Darolutamide"
],
[
"Darol... | Grazoprevir may lead to a major life threatening interaction when taken with Darolutamide and Darolutamide may cause a minor interaction that can limit clinical effects when taken with Entrectinib
Grazoprevir may lead to a major life threatening interaction when taken with Simvastatin and Simvastatin may cause a modera... |
DB08930 | DB14568 | 1,459 | 982 | [
"DDInter582",
"DDInter1000"
] | Dolutegravir | Ivosidenib | Dolutegravir is an HIV-1 integrase inhibitor that blocks the strand transfer step of the integration of the viral genome into the host cell (INSTI). The effect of this drug has no homology in human host cells, which gives it excellent tolerability and minimal toxicity. Dolutegravir was developed by ViiV Healthcare and ... | Ivosidenib is a first-in-class isocitrate dehydrogenase-1 (IDH1) inhibitor. IDH1 is an enzyme that is often mutated and overexpressed in some cancers, leading to aberrant cell growth and proliferation. Ivosidenib inhibits mutated IDH1, blocking the enzymatic activity and further differentiation of cancer cells. Ivoside... | Minor | 0 | [
[
[
1459,
23,
982
]
],
[
[
1459,
62,
1101
],
[
1101,
23,
982
]
],
[
[
1459,
62,
1478
],
[
1478,
24,
982
]
],
[
[
1459,
25,
286
],
[
286,
... | [
[
[
"Dolutegravir",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Ivosidenib"
]
],
[
[
"Dolutegravir",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Bexarotene"
],
[
... | Dolutegravir may cause a minor interaction that can limit clinical effects when taken with Bexarotene and Bexarotene may cause a minor interaction that can limit clinical effects when taken with Ivosidenib
Dolutegravir may cause a minor interaction that can limit clinical effects when taken with Ivacaftor and Ivacaftor... |
DB00307 | DB00673 | 1,101 | 723 | [
"DDInter202",
"DDInter112"
] | Bexarotene | Aprepitant | Bexarotene (Targretin) is an antineoplastic agent indicated by the FDA for Cutaneous T cell lymphoma. It has been used off-label for lung cancer, breast cancer, and Kaposi's sarcoma. | Aprepitant, an antiemetic, is a substance P/neurokinin 1 (NK1) receptor antagonist which, in combination with other antiemetic agents, is indicated for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy. Aprepitant is a selective h... | Minor | 0 | [
[
[
1101,
23,
723
]
],
[
[
1101,
23,
875
],
[
875,
40,
723
]
],
[
[
1101,
6,
8374
],
[
8374,
45,
723
]
],
[
[
1101,
21,
28770
],
[
28770,
... | [
[
[
"Bexarotene",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Aprepitant"
]
],
[
[
"Bexarotene",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Fosaprepitant"
],
[
... | Bexarotene may cause a minor interaction that can limit clinical effects when taken with Fosaprepitant and Fosaprepitant (Compound) resembles Aprepitant (Compound)
Bexarotene (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Aprepitant (Compound)
Bexarotene (Compound) causes Haematuria (Side Effect) and Haem... |
DB01081 | DB01200 | 1,688 | 469 | [
"DDInter571",
"DDInter243"
] | Diphenoxylate | Bromocriptine | A meperidine congener used as an antidiarrheal, usually in combination with atropine. At high doses, it acts like morphine. Its unesterified metabolite difenoxin has similar properties and is used similarly. It has little or no analgesic activity. This medication is classified as a Schedule V under the Controlled Subst... | Bromocriptine mesylate is a semisynthetic ergot alkaloid derivative with potent dopaminergic activity. It inhibits prolactin secretion and may be used to treat dysfunctions associated with hyperprolactinemia. Bromocriptine is also indicated for the management of signs and symptoms of Parkinsonian Syndrome, as well as t... | Moderate | 1 | [
[
[
1688,
24,
469
]
],
[
[
1688,
24,
649
],
[
649,
63,
469
]
],
[
[
1688,
63,
128
],
[
128,
24,
469
]
],
[
[
1688,
40,
1118
],
[
1118,
... | [
[
[
"Diphenoxylate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bromocriptine"
]
],
[
[
"Diphenoxylate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clofedanol"
],... | Diphenoxylate may cause a moderate interaction that could exacerbate diseases when taken with Clofedanol and Clofedanol may cause a moderate interaction that could exacerbate diseases when taken with Bromocriptine
Diphenoxylate may cause a moderate interaction that could exacerbate diseases when taken with Dexbrompheni... |
DB00471 | DB15093 | 201 | 1,654 | [
"DDInter1242",
"DDInter1698"
] | Montelukast | Somapacitan | Montelukast was first approved for clinical use by the US FDA in 1998 as Merck's brand name Singulair. The medication is a member of the leukotriene receptor antagonist (LTRA) category of drugs.[L6301,L6304,L6307,L6310,L6325,L6328,L6331] Although capable of demonstrating effectiveness, the use of such LTRAs like montel... | Somapacitan, also known as NNC0195-0092, is a growth hormone analog indicated to treat adults with growth hormone deficiency.[A219126,L15661] This human growth hormone analog differs by the creation of an albumin binding site, and prolonging the effect so that it requires weekly dosing rather than daily. Somapacitan wa... | Moderate | 1 | [
[
[
201,
24,
1654
]
],
[
[
201,
24,
1419
],
[
1419,
24,
1654
]
],
[
[
201,
63,
1324
],
[
1324,
24,
1654
]
],
[
[
201,
63,
1101
],
[
1101,
... | [
[
[
"Montelukast",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Somapacitan"
]
],
[
[
"Montelukast",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Imatinib"
],
[
... | Montelukast may cause a moderate interaction that could exacerbate diseases when taken with Imatinib and Imatinib may cause a moderate interaction that could exacerbate diseases when taken with Somapacitan
Montelukast may cause a moderate interaction that could exacerbate diseases when taken with Troglitazone and Trogl... |
DB01098 | DB11644 | 14 | 647 | [
"DDInter1622",
"DDInter1737"
] | Rosuvastatin | Tafamidis | Rosuvastatin, also known as the brand name product Crestor, is a lipid-lowering drug that belongs to the statin class of medications, which are used to lower the risk of cardiovascular disease and manage elevated lipid levels by inhibiting the endogenous production of cholesterol in the liver. More specifically, statin... | Tafamidis and tafamidis meglumine (FX-1006A) are benzoxazole derivatives developed by FoldRX. Tafamidis is structurally similar to diflusinal. Tafamidis was granted an EMA market authorisation on 16 November 2011 and FDA approval on 3 May 2019. | Moderate | 1 | [
[
[
14,
24,
647
]
],
[
[
14,
24,
72
],
[
72,
24,
647
]
],
[
[
14,
63,
663
],
[
663,
24,
647
]
],
[
[
14,
24,
72
],
[
72,
63,
1... | [
[
[
"Rosuvastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tafamidis"
]
],
[
[
"Rosuvastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Eltrombopag"
],
... | Rosuvastatin may cause a moderate interaction that could exacerbate diseases when taken with Eltrombopag and Eltrombopag may cause a moderate interaction that could exacerbate diseases when taken with Tafamidis
Rosuvastatin may cause a moderate interaction that could exacerbate diseases when taken with Methotrexate and... |
DB00278 | DB00554 | 291 | 1,027 | [
"DDInter117",
"DDInter1478"
] | Argatroban | Piroxicam | Argatroban is a direct, selective thrombin inhibitor. The American College of Cardiologists (ACC) recommend using bivalirudin or argatroban in patients who have had, or at risk for, heparin induced thrombocytopenia (HIT) and are undergoing percutaneous coronary intervention. Argatroban is a non-heparin anticoagulant sh... | A cyclooxygenase inhibiting, non-steroidal anti-inflammatory agent (NSAID) that is well established in treating rheumatoid arthritis and osteoarthritis and used for musculoskeletal disorders, dysmenorrhea, and postoperative pain. Its long half-life enables it to be administered once daily. | Moderate | 1 | [
[
[
291,
24,
1027
]
],
[
[
291,
24,
1171
],
[
1171,
1,
1027
]
],
[
[
291,
24,
222
],
[
222,
63,
1027
]
],
[
[
291,
24,
1061
],
[
1061,
... | [
[
[
"Argatroban",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Piroxicam"
]
],
[
[
"Argatroban",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Meloxicam"
],
[
... | Argatroban may cause a moderate interaction that could exacerbate diseases when taken with Meloxicam and Meloxicam (Compound) resembles Piroxicam (Compound)
Argatroban may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine and Sibutramine may cause a moderate interaction that could ... |
DB00280 | DB00682 | 494 | 126 | [
"DDInter575",
"DDInter1951"
] | Disopyramide | Warfarin | A class I anti-arrhythmic agent (one that interferes directly with the depolarization of the cardiac membrane and thus serves as a membrane-stabilizing agent) with a depressant action on the heart similar to that of guanidine. It also possesses some anticholinergic and local anesthetic properties. | Warfarin is an anticoagulant drug normally used to prevent blood clot formation as well as migration. Although originally marketed as a pesticide (d-Con, Rodex, among others), Warfarin has since become the most frequently prescribed oral anticoagulant in North America. Warfarin has several properties that should be not... | Minor | 0 | [
[
[
494,
23,
126
]
],
[
[
494,
40,
11244
],
[
11244,
40,
126
]
],
[
[
494,
24,
1376
],
[
1376,
40,
126
]
],
[
[
494,
6,
6943
],
[
6943,
... | [
[
[
"Disopyramide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Warfarin"
]
],
[
[
"Disopyramide",
"{u} (Compound) resembles {v} (Compound)",
"Pheniramine"
],
[
"Pheniramine",
"{u} (Compound) resemb... | Disopyramide (Compound) resembles Pheniramine (Compound) and Pheniramine (Compound) resembles Warfarin (Compound)
Disopyramide may cause a moderate interaction that could exacerbate diseases when taken with Diphenhydramine and Diphenhydramine (Compound) resembles Warfarin (Compound)
Disopyramide (Compound) binds ORM1 (... |
DB00798 | DB01329 | 1,132 | 1,458 | [
"DDInter815",
"DDInter322"
] | Gentamicin | Cefoperazone | Gentamicin is a bactericidal aminoglycoside that was discovered and isolated from _Micromonospora purpurea_ in 1963. It is one of the most frequently prescribed aminoglycosides due to its spectrum of activity, low cost, and availability.[A234339,A234354] Gentamicin is effective against both gram-positive and gram-negat... | Cefoperazone is a semisynthetic broad-spectrum cephalosporin proposed to be effective against <i>Pseudomonas</i> infections. It is a third-generation antiobiotic agent and it is used in the treatment of various bacterial infections caused by susceptible organisms in the body, including respiratory tract infections, per... | Moderate | 1 | [
[
[
1132,
24,
1458
]
],
[
[
1132,
63,
277
],
[
277,
1,
1458
]
],
[
[
1132,
24,
1402
],
[
1402,
40,
1458
]
],
[
[
1132,
24,
1227
],
[
1227,... | [
[
[
"Gentamicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cefoperazone"
]
],
[
[
"Gentamicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cefmetazole"
],
[... | Gentamicin may cause a moderate interaction that could exacerbate diseases when taken with Cefmetazole and Cefmetazole (Compound) resembles Cefoperazone (Compound)
Gentamicin may cause a moderate interaction that could exacerbate diseases when taken with Cefotetan and Cefotetan (Compound) resembles Cefoperazone (Compou... |
DB00289 | DB09122 | 847 | 1,613 | [
"DDInter132",
"DDInter1409"
] | Atomoxetine | Peginterferon beta-1a | Atomoxetine is a selective norepinephrine (NE) reuptake inhibitor used for the treatment of attention deficit hyperactivity disorder (ADHD). Also known as the marketed product Strattera, atomoxetine is used with other treatment modalities (psychological, educational, cognitive behaviour therapy, etc) to improve develop... | Multiple Sclerosis (MS) is a chronic and inflammatory autoimmune disease of the central nervous system, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years... | Moderate | 1 | [
[
[
847,
24,
1613
]
],
[
[
847,
63,
600
],
[
600,
24,
1613
]
],
[
[
847,
24,
1383
],
[
1383,
63,
1613
]
],
[
[
847,
24,
267
],
[
267,
... | [
[
[
"Atomoxetine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Peginterferon beta-1a"
]
],
[
[
"Atomoxetine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fluconazole"
... | Atomoxetine may cause a moderate interaction that could exacerbate diseases when taken with Fluconazole and Fluconazole may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon beta-1a
Atomoxetine may cause a moderate interaction that could exacerbate diseases when taken with Sodium... |
DB00424 | DB01400 | 19 | 1,372 | [
"DDInter896",
"DDInter1279"
] | Hyoscyamine | Neostigmine | Hyoscyamine is a tropane alkaloid and the levo-isomer of [atropine]. It is commonly extracted from plants in the _Solanaceae_ or nightshade family. Research into the action of hyoscyamine in published literature dates back to 1826. Hyoscyamine is used for a wide variety of treatments and therapeutics due to its antimus... | A cholinesterase inhibitor used in the treatment of myasthenia gravis and to reverse the effects of muscle relaxants such as gallamine and tubocurarine. Neostigmine, unlike physostigmine, does not cross the blood-brain barrier. | Moderate | 1 | [
[
[
19,
24,
1372
]
],
[
[
19,
24,
751
],
[
751,
40,
1372
]
],
[
[
19,
24,
61
],
[
61,
24,
1372
]
],
[
[
19,
21,
28705
],
[
28705,
60... | [
[
[
"Hyoscyamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Neostigmine"
]
],
[
[
"Hyoscyamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pyridostigmine"
],
... | Hyoscyamine may cause a moderate interaction that could exacerbate diseases when taken with Pyridostigmine and Pyridostigmine (Compound) resembles Neostigmine (Compound)
Hyoscyamine may cause a moderate interaction that could exacerbate diseases when taken with Edrophonium and Edrophonium may cause a moderate interacti... |
DB01211 | DB04835 | 609 | 1,655 | [
"DDInter393",
"DDInter1125"
] | Clarithromycin | Maraviroc | Clarithromycin, a semisynthetic macrolide antibiotic derived from erythromycin, inhibits bacterial protein synthesis by binding to the bacterial 50S ribosomal subunit. Binding inhibits peptidyl transferase activity and interferes with amino acid translocation during the translation and protein assembly process. Clarith... | Maraviroc (brand-named Selzentry, or Celsentri outside the U.S.) is a chemokine receptor antagonist drug developed by the drug company Pfizer that is designed to act against HIV by interfering with the interaction between HIV and CCR5. It was originally labelled as UK-427857 during development but was assigned the Mara... | Major | 2 | [
[
[
609,
25,
1655
]
],
[
[
609,
6,
8374
],
[
8374,
45,
1655
]
],
[
[
609,
18,
7247
],
[
7247,
57,
1655
]
],
[
[
609,
21,
28792
],
[
28792,... | [
[
[
"Clarithromycin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Maraviroc"
]
],
[
[
"Clarithromycin",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"... | Clarithromycin (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Maraviroc (Compound)
Clarithromycin (Compound) downregulates NPDC1 (Gene) and NPDC1 (Gene) is downregulated by Maraviroc (Compound)
Clarithromycin (Compound) causes Gastrointestinal disorder (Side Effect) and Gastrointestinal disorder (Side Eff... |
DB00962 | DB04837 | 1,639 | 649 | [
"DDInter1957",
"DDInter407"
] | Zaleplon | Clofedanol | Zaleplon is a sedative/hypnotic, mainly used for insomnia. It is known as a nonbenzodiazepine hypnotic. Zaleplon interacts with the GABA receptor complex and shares some of the pharmacological properties of the benzodiazepines. Zaleplon is a schedule IV drug in the United States. | Clofedanol is a centrally-acting cough suppressant available in Canada under the trade name Ulone. It is not available in the United States. | Moderate | 1 | [
[
[
1639,
24,
649
]
],
[
[
1639,
24,
1376
],
[
1376,
24,
649
]
],
[
[
1639,
63,
832
],
[
832,
40,
649
]
],
[
[
1639,
63,
701
],
[
701,
... | [
[
[
"Zaleplon",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clofedanol"
]
],
[
[
"Zaleplon",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diphenhydramine"
],
[
... | Zaleplon may cause a moderate interaction that could exacerbate diseases when taken with Diphenhydramine and Diphenhydramine may cause a moderate interaction that could exacerbate diseases when taken with Clofedanol
Zaleplon may cause a moderate interaction that could exacerbate diseases when taken with Tripelennamine ... |
DB00215 | DB01211 | 1,230 | 609 | [
"DDInter388",
"DDInter393"
] | Citalopram | Clarithromycin | Citalopram is an antidepressant belonging to the class of selective _serotonin-reuptake inhibitors_ (SSRIs) widely used to treat the symptoms of depression. It is a racemic bicyclic phthalate derivate and is the only compound with a tertiary amine and 2 nitrogen-containing metabolites among all SSRIs.[A261316,A14720] C... | Clarithromycin, a semisynthetic macrolide antibiotic derived from erythromycin, inhibits bacterial protein synthesis by binding to the bacterial 50S ribosomal subunit. Binding inhibits peptidyl transferase activity and interferes with amino acid translocation during the translation and protein assembly process. Clarith... | Major | 2 | [
[
[
1230,
25,
609
]
],
[
[
1230,
6,
4973
],
[
4973,
45,
609
]
],
[
[
1230,
18,
6351
],
[
6351,
57,
609
]
],
[
[
1230,
21,
28879
],
[
28879... | [
[
[
"Citalopram",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Clarithromycin"
]
],
[
[
"Citalopram",
"{u} (Compound) binds {v} (Gene)",
"ABCB1"
],
[
"ABCB1",
"{u} (Gene) is bound by {v} (Compound)",
"Clari... | Citalopram (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Clarithromycin (Compound)
Citalopram (Compound) downregulates COTL1 (Gene) and COTL1 (Gene) is downregulated by Clarithromycin (Compound)
Citalopram (Compound) causes Gingival bleeding (Side Effect) and Gingival bleeding (Side Effect) is caused by Cl... |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.